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Mammalian	  Target	  of	  Rapamycin	  (mTOR)	  forms	  two	  distinct	  protein	  kinase	  
complexes	  termed	  mTOR	  complex	  1	  (mTORC1)	  and	  mTOR	  complex	  2	  (mTORC2)	  
and	  reside	  in	  the	  center	  of	  complex	  cellular	  signaling	  networks	  that	  integrates	  
extracellular	  stimuli	  and	  intracellular	  status	  to	  maintain	  cellular	  integrity	  and	  
function.	  Proper	  regulation	  of	  mTORC1	  signaling	  is	  required	  for	  organism	  
development,	  function	  and	  aging.	  Persistent	  increases	  in	  mTORC1	  activity	  are	  
associated	  with	  diseases	  such	  as	  cancer,	  diabetes	  and	  neurodegeneration.	  Here	  we	  
examine	  how	  mTORC1	  is	  activated	  in	  neurons,	  and	  the	  neuropathological	  
consequences	  of	  persistent	  increase	  of	  mTORC1	  signaling.	  
Ras	  homology	  enriched	  in	  brain	  1	  (Rheb1)	  is	  an	  immediate	  early	  gene	  and	  a	  
small	  GTPase	  that	  contributes	  to	  mTORC1	  signaling.	  Characterization	  of	  a	  
conditional	  Rheb1	  knockout	  (KO)	  mouse	  line,	  demonstrates	  Rheb1	  is	  essential	  for	  
mTORC1	  signaling.	  Biochemical	  studies	  show	  Rheb1	  is	  enriched	  in	  synaptic	  vesicle	  
fractions.	  myc-­‐Rheb1	  (S16H)	  immunoprecipitation	  from	  the	  forebrains	  of	  
conditional	  over-­‐expresser	  mice	  show	  enrichment	  for	  ubiquitinylated	  proteins,	  
selective	  synaptic	  proteins	  and	  synaptic	  vesicle	  associated	  proteins.	  
Pharmacological	  modulation	  studies	  in	  cultured	  neurons	  provide	  a	  model	  of	  
Rheb1’s	  contribution	  to	  mTORC1	  activation	  through	  group	  I	  metabotropic	  




	   Conditional	  expression	  of	  myc-­‐Rheb1	  (S16H)	  provides	  a	  mouse	  model	  to	  
examine	  the	  consequences	  of	  persistent	  activation	  of	  mTORC1	  in	  brain.	  Behavioral	  
studies	  reveal	  prominent	  reduction	  of	  social	  motivation	  and	  reduced	  locomotor	  
activity	  in	  response	  to	  amphetamine	  treatment.	  Pharmacological	  and	  biochemical	  
analysis	  of	  the	  mTORC1	  signaling	  cascade	  in	  the	  striatum	  of	  the	  mutant	  mice	  reveals	  
inhibition	  of	  dopamine	  D1	  receptor	  signaling	  in	  combination	  with	  altered	  activities	  
in	  Protein	  phosphatase	  1	  (PP1),	  Protein	  phosphatase	  2A	  (PP2A)	  and	  dopamine-­‐	  and	  
cyclic	  AMP-­‐	  regulated	  phosphoprotein	  (DARPP-­‐32).	  Preliminary	  
electrophysiological	  studies	  support	  the	  hypothesis	  that	  persistent	  mTORC1	  
signaling	  inhibits	  D1	  dopamine	  receptor	  effects	  on	  corticostriatal	  plasticity.	  As	  D1	  
dopamine	  receptors	  provide	  an	  important	  reward	  signal	  in	  brain,	  these	  studies	  
suggest	  that	  reduced	  social	  motivation	  may	  be	  linked	  to	  failure	  of	  this	  behavior	  to	  
evoke	  reward.	  	  	  
These	  results	  provide	  molecular	  insights	  to	  mTORC1	  activation	  with	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Importance	  of	  understanding	  the	  cellular	  mechanisms	  underlying	  mTOR	  
signaling.	  
	  
The	  ability	  to	  adapt	  to	  environmental	  changes	  has	  contributed	  to	  the	  success	  
of	  living	  organisms	  in	  evolution.	  Factors	  that	  influence	  anabolism	  and	  catabolism	  in	  
cells	  include	  the	  abundance	  of	  oxygen,	  availability	  of	  nutrients,	  changes	  in	  stress	  and	  
energy	  levels.	  These	  influences	  ultimately	  determine	  the	  survival,	  and	  proliferation	  
of	  the	  organism.	  Cellular	  mechanisms	  that	  integrate	  environmental	  cues	  and	  
controls	  cellular	  functions	  accordingly	  ensure	  the	  cell’s	  survival,	  function	  and	  
proliferation.	  Mammalian	  Target	  of	  Rapamycin	  (mTOR)	  is	  a	  protein	  kinase	  that	  
resides	  in	  a	  complex	  signaling	  network,	  and	  integrates	  extra-­‐cellular	  and	  intra-­‐
cellular	  cues	  to	  regulate	  cellular	  functions.	  Thus,	  it	  is	  not	  surprising	  that	  genetic	  
mutations	  of	  the	  components	  in	  the	  mTOR	  signaling	  network	  or	  deregulation	  of	  the	  
network	  are	  associated	  with	  diseases	  such	  as	  diabetes,	  various	  forms	  of	  cancer,	  
lysosomal	  disease,	  Alzheimer’s	  Disease	  (AD),	  Autism	  Spectrum	  Disorder	  (ASD),	  
Schizophrenia,	  Fragile	  X	  syndrome,	  Huntington’s	  Disease	  (HD)	  among	  others	  
(Hoeffer	  and	  Klann).	  	  Studying	  the	  functions	  and	  the	  impact	  of	  alterations	  to	  the	  
mTOR	  signaling	  network	  will	  facilitate	  the	  advancement	  in	  fundamental	  biology	  and	  
therapeutics	  development.	  
	  
Discovery	  and	  characterization	  of	  mTOR	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Rapamycin,	  an	  anti-­‐proliferative	  compound,	  is	  a	  macrolide	  produced	  by	  
Streptomyces	  Hygroscopicus.	  In	  studying	  the	  mechanisms	  of	  Rapamycin,	  Target	  of	  
Rapamycin	  -­1	  and	  -­2	  (TOR1,	  TOR2)	  was	  identified	  through	  a	  genetic	  screen	  assay	  in	  
yeast	  (Cafferkey,	  Young	  et	  al.).	  A	  single	  gene	  FRAP1	  encodes	  the	  ortholog	  of	  TOR	  in	  
mammals	  termed	  mammalian	  Target	  of	  Rapamycin	  (mTOR)	  and	  is	  ubiquitously	  
expressed	  throughout	  the	  body	  including	  nervous,	  vascular	  and	  immune	  systems	  
(Maiese,	  Chong	  et	  al.)	  (Sabatini,	  Erdjument-­‐Bromage	  et	  al.).	  Characterization	  studies	  
of	  mTOR	  revealed	  that	  it	  is	  a	  2549	  amino	  acid	  serine/threonine	  kinase	  that	  belongs	  
to	  the	  phosphoinosidite	  3-­‐kinase	  protein	  (PI3K)	  kinase	  family	  (Hoeffer	  and	  Klann).	  
More	  than	  20	  Huntington,	  Elongation	  Factor	  3,	  A	  subunit	  of	  P2A,	  TOR1	  (HEAT)	  
domain	  repeats	  are	  located	  in	  the	  N-­‐terminal	  domain	  of	  the	  protein	  and	  mediate	  
protein-­‐protein	  interactions	  to	  form	  distinctive	  protein	  complexes.	  Biochemical	  and	  
genetic	  studies	  have	  shown	  that	  mTOR	  exists	  in	  two	  distinct	  protein	  complexes.	  
mTOR	  complex	  1	  (mTORC1)	  associates	  with	  a	  protein	  termed	  Raptor,	  while	  mTOR	  
complex	  2	  (mTORC2)	  associates	  with	  Rictor	  protein.	  In	  addition	  to	  these	  two	  
protein	  partners	  of	  mTOR,	  many	  other	  proteins	  identified	  are	  shared	  between	  the	  
complexes	  (Laplante	  and	  Sabatini).	  The	  C-­‐terminal	  portion	  of	  mTOR	  contains	  
several	  functional	  domains.	  FKBP12-­‐rapamycin	  binding	  domain	  (FRB)	  is	  bound	  by	  
the	  FKBP-­‐rapamycin	  complex	  and	  represents	  the	  rapamycin	  dependent	  site	  for	  
mTOR	  activity	  (Hoeffer	  and	  Klann).	  Two	  Transactivation/transformation	  domain-­‐
associated	  protein	  (TRRAP)	  domains	  that	  are	  conserved	  with	  PIKK	  family	  members	  
are	  necessary	  for	  mTOR	  catalytic	  function.	  The	  catalytic	  or	  kinase	  (KIN)	  domain	  
encodes	  the	  serine/threonine	  kinase	  activity	  of	  mTOR	  (Hoeffer	  and	  Klann).	  The	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aforementioned	  domains	  are	  integral	  for	  mTOR	  to	  function	  in	  an	  ever-­‐expanding	  
complex	  signaling	  network	  (Laplante	  and	  Sabatini).	  	  
	  
Rheb	  and	  its	  role	  in	  mTOR	  signaling	  
Ras	  homology	  enriched	  in	  brain	  1	  (Rheb1)	  was	  identified	  as	  an	  immediate	  
early	  gene	  induced	  by	  neuronal	  activity	  in	  the	  brain	  (Yamagata,	  Sanders	  et	  al.).	  
Characterization	  studies	  demonstrated	  Rheb	  is	  a	  small	  GTPase	  that	  is	  a	  member	  of	  
the	  Ras	  superfamily,	  and	  most	  highly	  conserved	  with	  hRas	  (Yamagata,	  Sanders	  et	  
al.).	  Sequence	  analysis	  identified	  a	  CAAX	  box	  at	  the	  carboxylterminal	  sequence	  
allowing	  for	  post-­‐translational	  farnesylation	  modification	  (Yamagata,	  Sanders	  et	  al.).	  
While	  studies	  have	  shown	  Tuberous	  sclerosis	  complex	  (Tsc)	  coupling	  to	  mTOR	  
activity,	  the	  mechanism	  remained	  elusive	  until	  through	  a	  genetic	  epistasis	  screens	  in	  
Drosophila	  melanogaster	  revealed	  that	  Rheb1	  was	  positioned	  down-­‐stream	  of	  Tsc	  
and	  up-­‐stream	  of	  mTOR	  (Saucedo,	  Gao	  et	  al.).	  	  Follow	  up	  studies	  indicated	  Tsc	  
complex	  is	  comprised	  of	  Tsc1	  and	  Tsc2	  proteins	  and	  possesses	  GTP	  Activating	  
Protein	  (GAP)	  activity	  that	  inactivates	  mTOR	  through	  Rheb1	  (Zhang,	  Gao	  et	  al.).	  Tsc	  
negatively	  regulates	  mTOR	  by	  increasing	  the	  intrinsic	  GTPase	  rate	  of	  Rheb1	  yielding	  
a	  GDP	  bound	  Rheb1	  that	  is	  incapable	  of	  stimulating	  mTOR	  kinase	  activity.	  Through	  
an	  alanine	  mutagenesis	  screen	  approach	  it	  was	  revealed	  that	  serine	  16	  mutation	  to	  
histidine	  reduces	  the	  GAP	  activity	  of	  Tsc	  on	  Rheb1,	  thus	  resulting	  in	  an	  increase	  in	  
mTOR	  kinase	  activity	  (Tabancay,	  Gau	  et	  al.).	  
	  
mTOR	  signaling	  pathway	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mTOR	  signaling	  has	  been	  a	  focus	  for	  investigators	  encompassing	  all	  
biological	  research	  as	  it	  is	  involved	  in	  many	  aspect	  of	  cellular	  functions.	  The	  
initiation	  of	  the	  signaling	  cascade	  can	  be	  triggered	  by	  intra-­‐	  and	  extra-­‐cellular	  
stimuli.	  However,	  the	  canonical	  signaling	  usually	  starts	  from	  a	  cell	  surface	  receptor	  
such	  as	  receptor	  tyrosine	  kinase	  (RTK)	  or	  insulin	  receptor.	  Ligand	  binding	  triggers	  
dimerization	  of	  the	  RTK	  and	  activates	  Phosphoinositide	  3-­‐kinase	  (PI3K).	  PI3K	  
phosphorylates	  Phosphatidylinositol	  4,5-­‐bisphosphate	  (PIP2)	  to	  
Phosphatidylinositol	  3,4,5-­‐triphosphate	  (PIP3),	  and	  thus	  activates	  Phosphoinisitol	  
dependent	  kinase	  1	  (PDK1).	  This	  step	  is	  also	  regulated	  by	  a	  phosphatase,	  
Phosphatase	  and	  tensin	  homolog	  (Pten).	  PDK1	  activates	  Akt,	  which	  in	  turn	  regulates	  
targets	  that	  are	  involved	  in	  cell	  survival,	  metabolism	  and	  proliferation.	  Akt	  also	  
inhibits	  Tsc,	  which	  is	  a	  negative	  regulator	  of	  Rheb1.	  GTP	  bound	  Rheb1	  activates	  
mTOR	  kinase	  that	  phosphorylates	  target	  proteins	  such	  as	  eukaryotic	  translation	  
Initiation	  Factor	  4E	  binding	  protein	  (eIF4E-­‐BP)	  and	  s6	  kinase	  (s6K)	  to	  increase	  
protein	  translation	  and	  inhibit	  autophagy	  (Laplante	  and	  Sabatini).	  In	  addition	  to	  the	  
extra-­‐cellular	  stimuli,	  other	  cellular	  status	  changes	  can	  also	  influence	  mTOR	  activity	  
through	  other	  proteins.	  Studies	  have	  shown	  hypoxia	  and	  energy	  depletion	  inhibits	  
mTOR	  through	  Tsc	  by	  Hypoxia	  Induced	  Factor	  1	  (HIF1)	  and	  5’	  adenosine	  
monophosphate-­‐activated	  protein	  kinase	  (AMPK)	  correspondingly.	  On	  the	  contrary,	  
amino	  acids	  can	  elevate	  mTOR	  kinase	  activity	  through	  an	  alternate	  PI3	  kinase,	  
VPS34	  (Gulati,	  Gaspers	  et	  al.).	  	  
One	  effecter	  of	  the	  mTORC1	  signaling	  is	  the	  ribosomal	  subunit	  s6,	  which	  
facilitates	  the	  scanning	  mechanism	  of	  the	  40S	  subunit	  to	  mediate	  translation	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initiation.	  Concomitantly,	  mTORC1	  phosphorylation	  of	  eukaryotic	  Initiation	  4E	  
binding	  protein	  (eIF4E-­‐BP)	  relieves	  its	  inhibition	  of	  the	  methyl-­‐7-­‐Guanosine	  (m7G)	  
cap	  binding	  of	  eukaryotic	  Initiation	  Factor	  4E.	  Once	  relieved	  of	  its	  inhibition,	  eIF4E	  
interacts	  with	  eukaryotic	  initiation	  factor	  4G	  (eIF4G)	  and	  Poly	  A	  Binding	  Protein	  
(PABP)	  to	  form	  the	  initiation	  complex	  and	  allows	  for	  protein	  translation	  to	  take	  
place	  (Laplante	  and	  Sabatini).	  Moreover,	  previous	  investigations	  have	  demonstrated	  
that	  the	  activity	  of	  eukaryotic	  Elongation	  Factor	  2	  Kinase	  (eEF2K)	  to	  be	  inhibited	  by	  
s6	  kinase	  (s6K),	  a	  target	  of	  the	  mTORC1	  pathway.	  As	  the	  result	  of	  the	  activation	  of	  
mTORC1	  enhancing	  translation	  initiation	  while	  inhibiting	  eEF2K	  to	  facilitate	  
elongation,	  the	  global	  translation	  kinetics	  is	  enhanced.	  The	  canonical	  activation	  of	  
mTOR	  pathway	  has	  been	  well	  established.	  Activation	  of	  receptors	  such	  as	  Insulin	  
receptor	  or	  Trk	  B	  receptor	  leads	  to	  a	  kinase	  cascade	  activation	  of	  mTORC1	  through	  
PDK1,	  PI3K	  class	  I,	  Akt,	  Tsc1/2	  and	  Rheb-­‐1	  (Han,	  Chen	  et	  al.)	  (Figure	  1).	  
	  
mTOR	  and	  synaptic	  plasticity	  
Neuronal	  networks	  established	  by	  the	  electrochemical	  communications	  
between	  synapses	  of	  neurons	  provide	  a	  “platform”	  for	  memory	  storage	  and	  
retrieval.	  	  The	  physiological	  responsiveness	  of	  the	  synaptic	  connections	  is	  plastic	  
and	  can	  be	  modified	  through	  activity	  experiences.	  Plasticity	  is	  often	  defined	  
temporally	  with	  observable	  alterations	  occurring	  from	  seconds	  to	  years.	  Long-­‐term	  
depression	  (LTD)	  is	  an	  activity-­‐dependent	  reduction	  in	  the	  efficacy	  of	  the	  synapses,	  
while	  Long-­‐term	  potentiation	  (LTP)	  is	  an	  activity-­‐dependent	  enhancement	  of	  the	  
synaptic	  transmission	  (Malenka	  and	  Bear).	  LTP	  and	  LTD	  are	  influenced	  by	  neuronal	  
6	  
surface	  receptors	  and	  channels	  including	  N-­‐methyl-­‐D-­‐aspartate	  receptors	  (NMDA-­‐
R),	  α−amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	  acid	  receptors	  (AMPA-­‐R),	  
brain-­‐derived	  neurotrophic	  factors	  (BDNF)	  and	  dopaminergic	  and	  metabotropic	  
glutamate	  receptors	  (mGluRs)	  (Malenka	  and	  Bear).	  The	  mTOR	  signaling	  pathway	  is	  
coupled	  to	  these	  receptors	  to	  contribute	  to	  their	  signal	  output	  (Hoeffer	  and	  Klann).	  	  
Rapamycin	  has	  been	  a	  key	  reagent	  for	  establishing	  evidences	  of	  mTOR	  signaling	  in	  
synaptic	  plasticity.	  Seminal	  studies	  in	  Aplysia	  showed	  rapamycin	  blocked	  translation	  
elongation	  and	  long-­‐term	  facilitation	  (Yanow,	  Manseau	  et	  al.)	  (Carroll,	  Warren	  et	  
al.).	  These	  findings	  provided	  a	  hint	  that	  TOR	  signaling	  participates	  in	  long-­‐lasting	  
plasticity	  changes.	  Studies	  in	  rats	  showed	  that	  rapamycin	  blocks	  late	  phase	  NMDA-­‐R	  
dependent	  hippocampal	  LTP	  (L-­‐LTP)	  suggesting	  a	  requirement	  for	  protein	  
translation	  mediated	  by	  mTOR	  to	  facilitate	  long	  lasting	  LTP	  (Tang	  and	  Schuman)	  
(Cammalleri,	  Lutjens	  et	  al.).	  Rapamycin	  and	  pharmacological	  inhibition	  of	  PI3K	  
upstream	  of	  mTOR	  is	  also	  reported	  to	  block	  mGluR-­‐dependent-­‐LTD	  (Banko,	  Hou	  et	  
al.).	  Moreover	  depotentiation	  by	  activation	  of	  mGluR	  in	  the	  hippocampus	  is	  reported	  
to	  be	  mTOR	  dependent	  (Zho,	  You	  et	  al.).	  These	  studies	  indicate	  that	  mTOR	  signaling	  
participates	  in	  different	  physiological	  outcomes	  to	  contribute	  to	  synaptic	  plasticity	  
in	  the	  brain.	  
	  
mTOR	  and	  neuropathological	  diseases	  
	   mTOR	  is	  a	  key	  integrator	  that	  resides	  in	  the	  center	  of	  signaling	  networks	  that	  
influence	  many	  aspects	  of	  cellular	  homeostasis,	  and	  crucial	  for	  cellular	  integrity	  
(Maiese,	  Chong	  et	  al.).	  	  In	  the	  central	  nervous	  system,	  unregulated	  mTOR	  signaling	  is	  
7	  
highly	  correlated	  with	  devastating	  neurodegenerative	  diseases.	  An	  increase	  in	  the	  
phosphorylation	  levels	  of	  mTOR	  and	  its	  substrates	  has	  been	  observed	  in	  AD,	  
suggestive	  that	  these	  substrates	  may	  promote	  AD	  progression	  (Griffin,	  Moloney	  et	  
al.).	  	  One	  exemplary	  substrate	  is	  p70S6K	  which	  associates	  with	  
hyperphosphorylated	  tau	  and	  neurofibrillary	  accumulation	  in	  AD	  patients	  (Maiese,	  
Chong	  et	  al.).	  Furthermore,	  mTOR	  inhibits	  autophagy,	  which	  mediates	  the	  
degradation	  of	  amyloid	  beta	  (Aß)	  (Wu,	  Feng	  et	  al.).	  Thus	  elevated	  mTOR	  activity	  
may	  lead	  to	  the	  accumulation	  of	  Aß	  in	  neurons.	  Increased	  accumulation	  of	  Aß	  is	  
toxic	  to	  neurons,	  microglias	  and	  other	  lymphocytes	  and	  leads	  to	  neurodegeneration	  
(Shang,	  Chong	  et	  al.).	  Mutations	  and	  functional	  disruptions	  in	  TSC1/2,	  PTEN	  and	  
EIF4E	  result	  in	  over-­‐activated	  mTOR	  signaling	  and	  have	  been	  demonstrated	  to	  lead	  
to	  autism-­‐relevant	  behaviors	  (Sawicka	  and	  Zukin)	  (Sharma,	  Hoeffer	  et	  al.)	  
(Schellenberg,	  Dawson	  et	  al.).	  	  Studies	  in	  a	  mouse	  model	  of	  Fragile	  X	  syndrome	  
(FXS),	  the	  most	  common	  heritable	  form	  of	  intellectual	  disability,	  also	  show	  elevated	  
mTOR	  signaling	  at	  the	  synapse	  (Sharma,	  Hoeffer	  et	  al.).	  These	  findings	  suggest	  
dysregulation	  of	  mTOR	  signaling	  as	  a	  unified	  pathological	  mechanism	  in	  FXS,	  
Tsc1/2,	  and	  Pten	  associated	  autism	  syndromes.	  	  
	   Schizophrenia	  is	  another	  neuropsychiatric	  illness	  that	  is	  linked	  to	  altered	  
signaling	  in	  the	  mTOR	  pathways.	  Schizophrenia	  is	  associated	  with	  multiple	  genetic	  
mutations	  and	  leads	  to	  a	  complex	  trait	  disorder	  manifested	  by	  severe	  
neurocognitive	  dysfunctions	  (Emamian).	  Genetic	  and	  biochemical	  studies	  have	  
converged	  on	  disrupted	  Akt	  signaling	  as	  one	  of	  the	  most	  consistent	  correlates	  in	  
humans	  and	  mouse	  models	  (Emamian).	  Since	  Akt	  resides	  upstream	  of	  mTOR	  in	  the	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signaling	  pathway,	  reduction	  in	  Akt	  signaling	  results	  in	  reduced	  mTOR	  signaling.	  	  
The	  reduction	  in	  mTOR	  signaling	  is	  in	  contrast	  to	  the	  other	  neurocognitive	  diseases	  
where	  mTOR	  signaling	  is	  elevated.	  However,	  recent	  findings	  that	  elevated	  mTOR	  
signaling	  leads	  to	  a	  negative	  feedback	  to	  Akt	  may	  reconcile	  the	  conflicting	  














CHAPTER	  2:	  	  
Materials	  and	  Methods	  
	  
Antibodies	  and	  drugs	  
The	  following	  antibodies	  previously	  described	  are	  commercially	  available	  
from	  Cell	  Signaling:	  anti-­‐ps6	  (S240/244)	  (rabbit	  polyclonal),	  anti-­‐s6	  (rabbit	  
polyclonal),	  anti-­‐p4EBP	  (T37/46)	  (rabbit	  polyclonal),	  anti-­‐4EBP	  (rabbit	  polyclonal),	  
anti-­‐pAkt	  (S308)	  (rabbit	  polyclonal),	  anti-­‐pAkt	  (S473)	  (rabbit	  polyclonal),	  anti-­‐
pTsc2	  (T1462)	  (rabbit	  polyclonal),	  anti-­‐Tsc2	  (rabbit	  polyclonal),	  anti-­‐pmTOR	  
(T1442)	  (rabbit	  polyclonal),	  anti-­‐mTOR	  (rabbit	  polyclonal)	  anti-­‐Actin	  (rabbit	  
polyclonal),	  anti-­‐pMek	  (S217/221)	  (rabbit	  polyclonal),	  anti-­‐pMapk	  (T202/Y204)	  
(rabbit	  polyclonal),	  anti-­‐pDarpp32	  (T34)	  (rabbit	  polyclonal),	  anti-­‐Rag	  (rabbit	  
polyclonal),	  anti-­‐Rab7	  (rabbit	  polyclonal),	  anti-­‐Rab4	  (rabbit	  polyclonal),	  anti-­‐
pGSKa/b	  (S21/9)	  (rabbit	  polyclonal),	  anti-­‐PP2A	  (rabbit	  polyclonal),	  anti-­‐pPP1a	  
(T320)	  (rabbit	  polyclonal),	  anti-­‐STIM1	  (rabbit	  polyclonal),	  anti-­‐STIM2	  (rabbit	  
polyclonal),	  anti-­‐Pan	  Calcineurin	  A	  (rabbit	  polyclonal),	  anti-­‐myc	  (rabbit	  polyclonal),	  
anti-­‐myc	  (mouse	  monoclonal),	  anti-­‐HA	  (rabbit	  polyclonal),	  anti-­‐DAT	  (rabbit	  
polyclonal).	  The	  following	  antibodies	  previously	  described	  are	  commercially	  
available	  from	  Santa	  Cruz:	  anti-­‐Shank3	  (rabbit	  polyclonal);	  from	  Sigma	  Aldrich:	  
anti-­‐DRD1	  (rat	  monoclonal);	  from	  Abcam:	  anti	  Lamp2	  (rat	  monoclonal),	  anti-­‐pPP2A	  
(Y307)	  (rabbit	  polyclonal);	  from	  Millipore:	  anti-­‐FK1	  (mouse	  monoclonal),	  anti-­‐
DRD2	  (rabbit	  polyclonal);	  from	  ENZO	  life	  sciences:	  anti-­‐RPT6	  (rabbit	  polyclonal);	  
GE	  healthcare:	  anti-­‐rabbit	  IgG-­‐HRP,	  anti-­‐mouse	  IgG-­‐HRP,	  anti-­‐rat.	  IgG-­‐HRP.	  Anti-­‐
10	  
NR1	  (rabbit	  polyclonal),	  anti-­‐NR2A	  (rabbit	  polyclonal),	  anti-­‐GluR1	  (rabbit	  
polyclonal),	  anti-­‐GluR2	  (mouse	  monoclonal)	  were	  kind	  gifts	  from	  Richard	  L.	  
Huganir.	  	  
MK-­‐801,	  Bay	  36-­‐7620,	  MPEP	  hydrochloride,	  AIDA,	  Bay	  K	  8644	  (R),	  Bay	  K	  
8644	  (S),	  MG132	  and	  Gadolinium	  chloride	  are	  commercially	  available	  through	  
Tocris.	  Rapamycin	  was	  purchase	  from	  LC	  laboratories.	  BDNF	  was	  purchased	  from	  
Invitrogen.	  Insulin	  and	  amino	  acids	  were	  from	  Sigma.	  	  
	  
Constructs	  
The	  full-­‐length	  and	  modified	  Orai,	  STIM1,	  Rheb1	  constructs	  have	  been	  
described	  previously	  (Yuan,	  Zeng	  et	  al.)	  (Zou,	  Zhou	  et	  al.).	  Full	  length	  Darpp32	  
construct	  was	  purchased	  from	  Addgene.	  
	  
Cell	  Culture	  and	  Transfection	  
Cell	  culture	  and	  transfection	  techniques	  were	  carried	  out	  as	  previously	  
described	  in	  (Park,	  Park	  et	  al.)	  (Zou,	  Zhou	  et	  al.).	  Neuronal	  cultures	  from	  embryonic	  
day	  18	  (E18)	  pups	  were	  prepared	  as	  reported	  previously	  (Rumbaugh,	  Sia	  et	  al.),	  
with	  minor	  alterations.	  For	  biochemistry	  experiments,	  0.4	  x	  106	  neurons	  were	  
added	  to	  each	  well	  of	  a	  6-­‐well	  plate	  (Corning)	  coated	  with	  poly-­‐L-­‐lysine.	  Growth	  
medium	  consisted	  of	  NeuroBasal	  (Invitrogen)	  supplemented	  with	  1%	  fetal	  bovine	  
serum	  (Hyclone),	  2%	  B27,	  1%	  Glutamax	  (Invitrogen),	  100U/mL	  penicillin,	  and	  
100U/mL	  streptomycin	  (Invitrogen).	  Neurons	  were	  fed	  twice	  per	  week	  with	  glia	  
conditioned	  growth	  medium.	  HEK293T	  cells	  were	  maintained	  in	  Dulbecco’s	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modified	  Eagle’s	  medium	  (DMEM)	  with	  Glutamax,	  containing	  10%	  heat-­‐inactivated	  
fetal	  bovine	  serum	  (Invitrogen),	  100U/mL	  penicillin,	  and	  100U/mL	  streptomycin	  at	  
37ºC	  and	  5%	  CO2.	  
	   Over-­‐expression	  of	  plasmids	  method	  utilized	  liposome	  vehicles	  with	  Fugene	  
6	  from	  Roche.	  Sinbis	  virus	  expression	  was	  prepared	  and	  carried	  out	  according	  to	  
manufacturer’s	  protocol	  (Invitrogen	  Cat:	  K750-­‐01).	  
	  
Immunoprecipitation	  assays	  
	   Indicated	  brain	  regions	  were	  dissected	  and	  lysis	  was	  carried	  out	  in	  ice	  cold	  1%	  
Triton-­‐X	  100	  IP	  buffer	  (1	  X	  PBS,	  pH	  7.4,	  with	  5	  mM	  EDTA,	  5	  mM	  EGTA,	  1	  mM	  
Na3VO4,	  10	  mM	  sodium	  pyrophosphate,	  50	  mM	  NaF,	  and	  1%	  Triton	  X-­‐100	  
containing	  Complete™	  EDTA-­‐Free	  protease	  inhibitors	  was	  added	  and	  vigorously	  
vortexed)	  or	  RIPA	  buffer	  +	  0.1%	  SDS	  	  (150	  mM	  NaCl	  1%	  NP-­‐40	  0.5%DOC	  
(deoxycholic	  acid)	  0.1%	  SDS,	  50mM	  Tris	  PH	  8.0	  1	  mM	  Na3VO4,	  10	  mM	  sodium	  
pyrophosphate,	  50	  mM	  NaF,	  and	  Complete™	  EDTA-­‐Free	  protease	  inhibitors	  was	  
added	  and	  vigorously	  vortexed)	  with	  .	  Lysate	  was	  sonicated	  and	  cleared	  by	  
centrifugation.	  50	  μl	  of	  anti-­‐myc	  coupled	  magnetic	  bead	  slurry	  (antibody	  coupling	  
procedure	  was	  carried	  out	  according	  to	  manufacturer’s	  protocol	  (Invitrogen	  Cat:	  
143.11D))	  was	  added	  to	  10	  ml	  of	  supernatant	  and	  rotated	  overnight	  at	  4°C.	  The	  
magnetic	  beads	  were	  washed	  three	  times	  with	  ice-­‐cold	  IP	  buffer.	  The	  protein	  
samples	  were	  eluted	  with	  100	  μl	  of	  SDS	  loading	  buffer	  and	  analyzed	  by	  SDS-­‐PAGE	  
followed	  Western	  blotting	  or	  silver	  staining	  (Invitrogen	  Cat:	  LC6070).	  Harvard	  
Taplin	  Mass	  Spectrometry	  Core	  Facility	  carried	  out	  Mass	  spectrometry	  analysis.	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Sub-­cellular	  fractionation	  assays	  
Sub-­‐cellular	  fractionation	  assays	  were	  carried	  out	  as	  described	  (Hallett,	  
Collins	  et	  al.)	  
	  
Western	  Blotting	  on	  Brain	  Lysates	  
Western	  blot	  procedures	  were	  carried	  out	  as	  previously	  described	  (Zou,	  
Zhou	  et	  al.).	  Brain	  extracts	  were	  made	  from	  indicated	  brain	  regions	  of	  mice	  (4weeks	  
–	  6	  months	  old)	  with	  lysis	  buffer	  (2%	  SDS	  with	  proteinase	  and	  phosphatase	  
inhibitors	  unless	  indicated	  otherwise).	  After	  quantification	  of	  the	  total	  amount	  of	  
proteins	  in	  each	  sample,	  the	  samples	  were	  loaded	  into	  SDS-­‐PAGE	  gels	  and	  blotted	  
with	  various	  antibodies,	  according	  to	  standard	  Western	  blotting	  procedures.	  	  
	  
Animal	  behavioral	  assays	  
Mice	  were	  generated	  on	  a	  mixed	  129s6;	  C57BL6/J	  background	  and	  
backcrossed	  with	  littermates	  for	  at	  least	  5	  generations.	  Male	  littermate	  mice	  were	  
used	  as	  controls	  in	  all	  behavior	  tests.	  All	  procedures	  involving	  animals	  were	  under	  
the	  guidelines	  of	  Johns	  Hopkins	  University	  Institutional	  Animal	  Care	  and	  Use	  
Committee.	  
Behaviors	  were	  recorded	  by	  computer-­‐based	  tracking	  systems	  (HVS	  Image	  
Analysis	  VP-­‐200,	  HVS	  Image,	  Hampton,	  England;	  Any	  Maze	  4.72,	  Stoelting	  Co,	  Wood	  
Dale,	  IL;	  Noldus,	  Ethovision	  2.3.19,	  SR-­‐LAB,	  San-­‐Diego	  Instruments,	  CA,	  USA)	  and	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scored	  when	  necessary	  by	  trained	  observers	  blind	  to	  genotype	  using	  computer-­‐
assisted	  data	  system.	  
	  
Acute	  Slice	  Preparation	  and	  Treatment	  
Acute	  slice	  preparations	  were	  carried	  out	  as	  previously	  described	  (Wu,	  
Petralia	  et	  al.).	  8-­‐	  to	  9-­‐week-­‐old	  mice	  were	  anesthetized	  with	  isoflourane	  and	  
decapitated	  upon	  disappearance	  of	  tail	  withdrawal	  reflex.	  The	  brain	  was	  removed	  
and	  immediately	  submerged	  in	  ice	  cold	  dissection	  buffer	  containing:	  2.6	  mM	  KCl,	  
1.25	  mM	  NaH2PO4,	  26	  mM	  NaHCO3,	  0.5	  mM	  CaCl2,	  5	  MgCl2,	  212	  mM	  sucrose,	  and	  
10	  mM	  dextrose.	  300	  μm	  coronal	  sections	  were	  made	  using	  a	  vibratome	  (VT	  1200S;	  
Leica,	  Nussloch,	  Germany).	  Only	  slices	  containing	  the	  hippocampus	  were	  used.	  
Slices	  were	  recovered	  for	  1	  hr	  at	  30°C	  in	  a	  reservoir	  chamber	  filled	  with	  ACSF	  
containing:	  124	  mM	  NaCl,	  3.25	  mM	  KCl,	  1.25	  mM	  NaH2PO4,	  26	  mM	  NaHCO3,	  2	  mM	  
CaCl2,	  1	  mM	  MgCl2,	  and	  11	  mM	  dextrose.	  ACSF	  and	  dissection	  buffer	  were	  
equilibrated	  with	  95%	  O2-­‐5%	  CO2.	  Slices	  were	  then	  placed	  in	  a	  12	  well	  culture	  plate	  
with	  500	  μm	  mesh	  inserts	  in	  1.8	  ml	  of	  ACSF	  +/−	  Picrotoxin.	  The	  culture	  plate	  was	  
covered	  loosely	  and	  maintained	  in	  a	  pre-­‐equilibrated	  static	  treatment	  chamber	  
(aerated	  with	  95%	  O2-­‐5%	  CO2)	  for	  ∼10	  hr	  at	  30°C.	  
	  
Electrophysiology	  	  
Electrophysiology	  procedures	  were	  carried	  out	  as	  previously	  described	  
(Park,	  Park	  et	  al.).	  Field	  recording	  of	  excitatory	  postsynaptic	  potential	  (fEPSP)	  of	  
hippocampal	  CA1	  neurons	  of	  postnatal	  day	  (P)21-­‐30	  male	  mice	  as	  described	  with	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minor	  modifications	  (Huber,	  Kayser	  et	  al.).	  mGluR-­‐LTD	  was	  induced	  by	  an	  
mGluR1/5	  agonist,	  (R,S)-­‐3,5-­‐DHPG,	  for	  5	  min	  (50	  or	  100	  µM),	  or	  by	  paired-­‐pulse	  
low-­‐frequency	  stimulation	  (PP-­‐LFS:	  50	  ms	  interstimulus	  interval,	  1	  Hz,	  for	  15	  min)	  
in	  the	  presence	  of	  D-­‐APV	  (50	  µM).	  NMDAR-­‐dependent	  LTD	  was	  induced	  by	  using	  
900	  single	  pulses	  delivered	  at	  1	  Hz	  (Huber,	  Kayser	  et	  al.).	  
LTP	  was	  measured	  in	  Schaffer	  collateral-­‐CA1	  synapses	  in	  hippocampal	  slices	  
derived	  from	  8-­‐	  to	  10-­‐weeks	  old	  male	  mice.	  Late-­‐phase	  LTP	  (L-­‐LTP)	  was	  induced	  by	  
four	  trains	  of	  high-­‐frequency	  stimulation	  (HFS)	  (100	  Hz,	  1	  s)	  with	  3	  s	  of	  intertrain	  
interval.	  
For	  recording,	  coronal	  brain	  hemislices	  were	  transferred	  to	  an	  interface	  type	  
chamber,	  maintained	  at	  32	  ºC	  for	  1hr,	  and	  perfused	  continuously	  with	  nominally	  
magnesium	  free-­‐ACSF	  at	  a	  rate	  of	  4-­‐5	  ml/min	  to	  reliably	  activate	  the	  N-­‐methyl-­‐D-­‐
aspartate	  receptor	  (NMDAR)	  (Calabresi,	  Pisani	  et	  al.).	  The	  recording	  electrodes	  
filled	  with	  0.9	  %	  NaCl	  were	  located	  in	  the	  dorsomedial	  striatum,	  as	  previously	  
described	  (Citri	  and	  Malenka).	  Extracellular	  field	  recordings	  were	  evoked	  by	  
stimulation	  of	  the	  white	  matters	  between	  the	  cortex	  and	  the	  striatum	  with	  a	  parallel	  
bipolar	  electrode	  (FHC,	  Bowdoin,	  ME).	  The	  test	  stimulus	  intensity	  was	  adjusted	  to	  
elicit	  30	  %	  of	  the	  maximal	  population	  spike	  (PS).	  Test	  stimuli	  were	  delivered	  every	  
30	  sec	  with	  0.1	  msec	  pulse	  duration.	  	  
A	  high	  frequency	  stimulation	  protocol	  (HFS,	  three	  3sec	  duration,	  100	  Hz	  
frequency,	  20	  sec	  interval)	  was	  used	  to	  induce	  long-­‐term	  potentiation	  (LTP)	  in	  the	  
dorsomedial	  striatum	  (Calabresi,	  Pisani	  et	  al.).	  The	  stimulus	  pulse	  duration	  of	  HFS	  
was	  0.2	  msec,	  which	  was	  two	  times	  stronger	  than	  the	  test	  stimulus.	  A	  low	  frequency	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stimulation	  (LFS,	  2Hz,	  10min)	  protocol	  was	  used	  to	  depotentiate	  LTP	  caused	  by	  
prior	  HFS	  (Calabresi,	  Pisani	  et	  al.).	  The	  stimulus	  pulse	  duration	  of	  LFS	  was	  0.1msec.	  
The	  amplitudes	  of	  the	  PS	  were	  normalized	  to	  baseline	  values	  (-­‐5	  min	  to	  0	  min)	  
before	  HFS.	  The	  n	  reported	  in	  figures	  is	  the	  number	  of	  slices.	  In	  all	  cases	  except	  
Figure	  7E,	  slices	  were	  obtained	  from	  >3	  mice.	  Recordings	  of	  WT	  mice	  in	  8E	  that	  
examined	  the	  effect	  of	  SKF38393	  used	  slices	  from	  2	  mice.	  	  
Tissue	  Processing,	  Immunohistochemistry	  and	  Electron	  Microscopy	  	  
For	  immunohistochemistry,	  mouse	  brains	  were	  prepared	  by	  cardiac	  
perfusion	  with	  cold	  PBS	  and	  4%	  PFA	  followed	  by	  one-­‐night	  post	  fixation	  in	  the	  same	  
solution	  at	  4°C.	  Fixed	  brains	  were	  dehydrated	  in	  30%	  sucrose	  before	  proceeding	  to	  
embedding	  for	  frozen	  section.	  Brain	  sections	  were	  blocked	  in	  1%	  BSA/10%	  goat	  
serum/0.3%	  Triton/PBS	  solution	  for	  1	  hour	  at	  RT,	  and	  stained	  with	  first	  antibodies	  
diluted	  in	  1%	  BSA/1%	  goat	  serum/0.3%	  Triton/PBS	  solution	  for	  overnight	  at	  4°C.	  
Secondary	  antibodies	  were	  diluted	  in	  PBS	  with	  1%	  goat	  serum	  and	  incubated	  for	  1	  
hour	  at	  RT.	  	  
For	  LFB	  staining,	  brain	  sections	  were	  stained	  in	  0.1%	  Luxol	  Fast	  Blue	  
solution	  as	  standard	  procedure	  and	  counter-­‐stained	  with	  0.5%	  eosin	  and	  0.1%	  
cresyl	  violet.	  Black	  Gold	  staining	  was	  performed	  as	  Manufacturer’s	  instructions	  
(Millipore).	  
For	  electron	  microscopy,	  mice	  were	  perfused	  with	  2%	  glutaraldehyde/2%	  
paraformaldehyde	  in	  0.1	  M	  cacodylate	  buffer.	  Corpus	  callosum	  and	  optic	  nerves	  
were	  dissected	  and	  post-­‐fixed	  overnight	  in	  the	  same	  fixative	  buffer.	  Tissues	  were	  
then	  processed	  as	  standard	  procedure	  before	  photograph.	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Surface	  biotinylation	  assays	  
Surface	  biotinylation	  assay	  was	  carried	  out	  as	  described	  (Park,	  Park	  et	  al.).	  
Briefly,	  drug-­‐treated	  cortical	  neurons	  were	  cooled	  on	  ice,	  washed	  twice	  with	  ice	  cold	  
PBS++	  (1X	  PBS,	  1	  mM	  CaCl2,	  0.5	  mM	  MgCl2)	  and	  then	  incubated	  with	  PBS++	  
containing	  1	  mg/ml	  Sulfo-­‐NHS-­‐SS-­‐Biotin	  (Pierce)	  for	  30	  min	  at	  4	  °C.	  Unreacted	  
biotin	  was	  quenched	  by	  washing	  cells	  three	  times	  with	  PBS++	  containing	  100	  mM	  
Glycine	  (pH	  7.4)	  (briefly	  once	  and	  for	  5	  min	  twice).	  Cultures	  were	  harvested	  in	  RIPA	  
buffer	  and	  sonicated.	  Homogenates	  were	  centrifuged	  at	  132,000	  rpm	  for	  20	  min	  at	  4	  
°C.	  Fifteen	  %	  of	  supernatant	  was	  saved	  as	  the	  total	  protein.	  The	  remaining	  85%	  of	  
the	  homogenate	  was	  rotated	  with	  Streptavidin	  beads	  (Pierce)	  for	  2	  hr.	  Precipitates	  
were	  washed	  with	  RIPA	  buffer	  three	  times	  (5	  min	  each	  time).	  All	  procedures	  were	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mTOR	  signaling	  resides	  at	  a	  node	  that	  coordinates	  cellular	  responses	  to	  
hypoxia,	  energy,	  DNA	  integrity,	  stress,	  amino	  acids	  and	  extracellular	  signals.	  As	  any	  
of	  these	  input	  changes	  in	  an	  aberrant	  manner,	  the	  mTOR	  integration	  pathway	  
becomes	  mis-­‐regulated,	  and	  diseases	  may	  arise.	  Examples	  of	  neurological	  diseases	  
that	  are	  suggested	  to	  be	  associated	  with	  alteration	  in	  mTOR	  signaling	  pathway	  
include	  Neurofibromatosis	  type	  1,	  Hamartomas,	  Alzheimer’s	  Disease,	  Huntington’s	  
Disease	  (Hoeffer	  and	  Klann).	  Most	  of	  the	  diseases	  associated	  with	  mTOR	  signaling	  
are	  due	  to	  a	  “gain	  of	  function”	  of	  the	  pathway	  wherein	  negative	  regulators	  of	  the	  
pathway	  are	  disrupted	  due	  to	  mutations.	  	  
Type	  2	  diabetes	  is	  a	  well-­‐characterized	  disease	  arising	  from	  persistent	  mTOR	  
signaling.	  Following	  the	  canonical	  extracellular	  signaling	  pathway;	  insulin	  binding	  
to	  the	  insulin	  receptor	  leads	  to	  the	  activation	  of	  the	  receptor,	  which	  in	  turn	  activates	  
Phosphoinositol	  3-­‐Kinase	  (PI3K).	  PI3K	  phosphorylates	  Phosphatidylinositol	  4,5-­‐
bisphosphate	  (PIP2)	  and	  yields	  Phosphatidylinositol	  3,4,5-­‐triphosphate	  (PIP3)	  thus	  
activating	  Phosphoinisitol	  dependent	  kinase	  1	  (PDK1).	  This	  step	  is	  regulated	  by	  a	  
phosphatase,	  Pten,	  a	  gene	  often	  mutated	  in	  diseases	  such	  as	  cancer.	  PDK1	  activates	  
Akt,	  which	  is	  a	  regulator	  of	  cell	  survival,	  metabolism	  and	  proliferation.	  Akt	  also	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inhibits	  the	  tuberous	  sclerosis	  complex	  (TSC1/2).	  TSC1/2	  possesses	  GTP	  Activating	  
Protein	  (GAP)	  function	  that	  inhibits	  a	  small	  GTPase	  Rheb1.	  Rheb1	  in	  turn	  activates	  
mTOR	  complex	  1	  (mTORC1),	  identified	  by	  association	  with	  the	  Regulatory-­‐
associated-­‐protein-­‐of-­‐mtor	  (Raptor).	  mTORC1	  regulates	  ribosome	  biogenesis,	  
autophagy	  and	  translation	  among	  other	  cellular	  processes	  (Figure	  1A).	  Through	  
evolution,	  cells	  have	  evolved	  a	  mechanism	  where	  activation	  of	  mTORC1	  reduces	  
insulin	  receptor	  signaling	  via	  Insulin	  Receptor	  Substrate	  (IRS)	  feedback	  inhibition.	  
However,	  in	  type	  2	  Diabetes,	  persistent	  mTORC1	  activity	  leads	  to	  chronic	  inhibition	  
of	  IRS	  and	  prevents	  transmission	  of	  extracellular	  signals	  and	  activation	  of	  proper	  
kinase	  cascade	  resulting	  in	  insulin	  resistance	  (Figure	  1B).	  Mechanistic	  and	  
functional	  studies	  of	  the	  mTOR	  pathway	  have	  utilized	  Rapamycin,	  which	  inhibits	  
mTORC1	  kinase	  activity	  with	  acute	  treatment	  thus	  revealing	  its	  regulations	  
(Sabatini,	  Erdjument-­‐Bromage	  et	  al.).	  
In	  my	  studies,	  we	  examined	  disruptions	  of	  the	  mTOR	  pathway	  in	  the	  brain	  
and	  determined	  that	  mTORC1	  signaling	  is	  dependent	  on	  Rheb1	  and	  that	  persistent	  
activation	  of	  mTORC1	  leads	  to	  down-­‐regulation	  of	  D1	  dopamine	  receptor	  signaling	  
in	  a	  manner	  analogous	  to	  down-­‐regulation	  of	  insulin-­‐receptor	  signaling	  in	  type	  2	  
diabetes.	  These	  observations	  have	  implications	  for	  understanding	  the	  impact	  of	  





The	  lab	  has	  generated	  genetically	  modified	  Rheb1	  mice	  to	  enable	  studies	  on	  
its	  contribution	  and	  function	  to	  mTOR	  signaling	  output	  (Zou,	  Zhou	  et	  al.)	  (Figure	  
4A).	  	  For	  our	  studies	  we	  utilized	  a	  conditional	  knockout	  mouse,	  where	  exon	  3	  was	  
floxed	  (Figure	  4B).	  In	  order	  to	  obtain	  a	  brain	  specific	  knockout	  mouse	  (KO),	  we	  
crossed	  the	  Rheb1	  floxed	  mouse	  (F/F)	  to	  a	  Nestin-­‐Cre	  mouse	  Rheb1	  mouse	  
containing	  one	  lox	  P	  site	  (F/+	  Nestin-­‐Cre).	  We	  compared	  lysates	  made	  from	  the	  
forebrain	  of	  KOs	  to	  control	  littermates	  by	  Western	  blot	  analysis.	  Rheb1	  was	  
efficiently	  excised	  in	  the	  KO.	  Moreover,	  Rheb1	  is	  absolutely	  required	  for	  mTORC1	  
function	  as	  demonstrated	  by	  the	  reduction	  in	  p-­‐s6	  and	  p-­‐4EBP.	  Interestingly,	  p-­‐Akt	  
(S473),	  which	  is	  upstream	  of	  mTORC1,	  showed	  an	  enhanced	  phosphorylation	  signal	  
(Figure	  4C).	  Published	  studies	  using	  heterologous	  systems	  suggested	  a	  feed	  back	  
regulation	  from	  mTORC1	  via	  s6	  Kinase	  to	  mTORC2,	  which	  phosphorylates	  Akt	  at	  
S473	  (Sarbassov,	  Guertin	  et	  al.).	  This	  feedback	  inhibition	  is	  important	  in	  tuning	  
down	  mTORC1	  activity	  during	  a	  chronic	  stimulation	  or	  maintaining	  mTORC1	  
activity	  during	  lack	  of	  input	  signals.	  Our	  study	  was	  the	  first	  in	  vivo	  demonstration	  of	  
this	  feedback	  loop	  (Zou,	  Zhou	  et	  al.).	  It	  is	  worth	  noting	  that	  brain	  structures	  were	  
not	  altered	  through	  development	  with	  size	  being	  the	  only	  observable	  difference	  
(Zou,	  Zhou	  et	  al.).	  	  
Another	  mouse	  line	  that	  we	  employed	  for	  our	  study	  was	  a	  myc-­‐tagged	  Rheb1	  
(S16H)	  transgene	  knocked	  into	  the	  Rosa	  locus	  (Figure	  4D)	  (Zou,	  Zhou	  et	  al.).	  The	  
S16H	  mutation	  yields	  a	  constitutively	  active	  Rheb1	  by	  reducing	  its	  sensitivity	  to	  the	  
GAP	  activity	  of	  TSC	  complex	  (Yan,	  Findlay	  et	  al.).	  	  We	  also	  crossed	  this	  mouse	  to	  a	  
Nestin-­‐Cre	  expressing	  mouse	  to	  generate	  a	  brain	  specific	  myc-­‐Rheb1	  (S16H)	  over-­‐
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expresser.	  Western	  blotting	  analysis	  of	  forebrain	  lysate	  from	  littermate	  control	  and	  
over-­‐expresser	  show	  that	  the	  myc-­‐Rheb1	  (S16H)	  is	  expressed	  (Figure	  4E).	  Rheb1	  
specific	  antibody	  detected	  endogenous	  Rheb1	  in	  both	  lysates	  and	  was	  also	  able	  to	  
detect	  myc-­‐Rheb1	  (S16H),	  which	  showed	  an	  increase	  in	  molecular	  weight	  due	  to	  the	  
addition	  of	  the	  myc	  epitope	  tag.	  In	  the	  over-­‐expresser	  mice,	  mTORC1	  activity	  is	  
increased	  with	  concomitant	  decrease	  in	  p-­‐Akt	  (S473)	  (Figure	  4E).	  This	  finding	  
shows	  that	  the	  feedback	  inhibition	  through	  mTORC2	  is	  preserved	  in	  this	  animal.	  The	  
brain	  structures	  developed	  normally	  with	  the	  over-­‐expresser	  animal	  showing	  an	  
increase	  in	  brain	  size	  (data	  not	  shown)	  (Zou,	  Zhou	  et	  al.).	  
Established	  studies	  have	  provided	  convincing	  genetic	  mutations	  of	  mTOR	  
pathway	  components	  contributing	  to	  ASD	  (Hoeffer	  and	  Klann).	  In	  collaboration	  Dr.	  
Alena	  Sovenenko	  in	  the	  Department	  of	  Pathobiology	  at	  Johns	  Hopkins	  School	  of	  
Medicine,	  we	  subjected	  the	  Nestin-­‐Cre	  myc-­‐Rheb1	  (S16H)	  mice	  to	  a	  battery	  of	  
behavioral	  tests.	  We	  examined	  the	  5-­‐month-­‐old	  male	  mutant	  mice	  and	  littermate	  
control	  mice	  in	  a	  social	  investigation	  paradigm	  (Figure	  5A).	  The	  assay	  presented	  a	  1-­‐
month-­‐old	  juvenile	  male	  mouse	  three	  consecutive	  times	  to	  the	  test	  mouse.	  In	  control	  
and	  mutant	  mice,	  robust	  habituation	  is	  observed,	  as	  the	  time	  of	  investigation	  
reduces	  significantly	  for	  each	  subsequent	  trial	  the	  same	  juvenile	  mouse	  is	  
presented.	  However,	  when	  a	  new	  1-­‐month-­‐old	  juvenile	  mouse	  is	  presented	  in	  trial	  4,	  
the	  test	  mouse	  spent	  significantly	  more	  time	  investigating	  the	  new	  juvenile,	  most	  
likely	  due	  to	  novelty	  recognition	  (Figure	  5B).	  	  It	  is	  worth	  noting	  that	  the	  quality	  of	  
investigation	  interaction	  of	  the	  mutant	  mice	  were	  not	  in	  an	  aggressive	  manner	  and	  
were	  comparable	  to	  control	  mice.	  We	  also	  employed	  the	  classic	  sociability	  test	  to	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examine	  the	  behaviors	  our	  cohorts.	  The	  behavior	  paradigm	  utilizes	  a	  three	  chamber	  
setup	  where	  the	  test	  mouse	  is	  placed	  in	  the	  middle	  chamber	  and	  has	  the	  choice	  to	  
explore	  a	  mouse	  held	  under	  a	  cup	  in	  another	  chamber	  (social	  chamber)	  or	  just	  a	  cup	  
by	  itself	  in	  the	  third	  chamber.	  Typically	  a	  mouse	  will	  spend	  more	  time	  investigating	  
the	  social	  chamber	  than	  the	  empty	  cup	  chamber.	  We	  found	  that	  mutant	  mice	  spend	  
significant	  less	  time	  investigating	  the	  social	  chamber	  compared	  to	  control	  mice,	  
while	  they	  both	  showed	  similar	  disinterest	  in	  the	  empty	  cup	  chamber	  (Figure	  5C).	  
Despite	  the	  social	  chamber	  preference	  trend	  being	  preserved	  in	  the	  mutant	  mice,	  
they	  did	  spend	  significantly	  more	  time	  in	  the	  neutral	  chamber	  in	  comparison	  to	  
their	  control	  littermates.	  Contacts	  made	  with	  the	  mouse	  under	  the	  cup	  were	  also	  
significantly	  less	  by	  the	  mutant	  mice	  compared	  to	  the	  control	  mice	  (Figure	  5C).	  Both	  
the	  mutant	  and	  control	  mice	  had	  very	  minimal	  contact	  with	  the	  empty	  cup.	  Though	  
dramatic	  differences	  in	  the	  social	  investigation	  behavior	  examinations	  were	  
observed,	  mutant	  mice	  performed	  very	  similarly	  to	  control	  mice	  in	  motor	  activity,	  
thigmotaxis,	  Y-­‐Maze,	  and	  Plus	  Maze	  assays	  (Figure	  5D).	  The	  comparable	  behavior	  
tests	  performances	  suggest	  that	  the	  social	  behavioral	  deficit	  was	  fairly	  selective.	  
Intrigued	  by	  the	  impaired	  social	  investigation	  results	  of	  the	  mutant	  mice	  we	  
examined	  striatum	  functions	  by	  employing	  assays	  that	  test	  motor	  activity	  induced	  
by	  amphetamine.	  Amphetamine	  increases	  locomotor	  activity	  related	  to	  the	  
dopamine	  and	  norepinephrine	  in	  the	  striatum	  by	  blocking	  dopamine	  transporters	  
(DAT)	  thus	  increasing	  synaptic	  dopamine	  levels	  (Yates,	  Meij	  et	  al.).	  Intraperitoneal	  
injection	  (i.p)	  of	  amphetamine	  induces	  motor	  activities	  that	  increases	  over	  a	  span	  of	  
30	  minutes	  and	  allows	  for	  quantification	  studies.	  To	  examine	  the	  impact	  of	  mTOR	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function	  in	  the	  striatum,	  we	  setup	  the	  following	  experimental	  paradigm	  (Figure	  6A).	  
5-­‐month-­‐old	  male	  control	  mice	  were	  allowed	  to	  habituate	  in	  an	  open	  field	  box	  for	  10	  
minutes	  and	  their	  motor	  activity	  were	  recorded.	  Subsequently,	  they	  were	  treated	  
with	  vehicle	  or	  rapamycin	  (10	  mg/kg	  i.p)	  and	  placed	  back	  into	  the	  open	  field	  box	  for	  
an	  acute	  inhibition	  of	  mTORC1.	  After	  another	  40	  minutes	  of	  habituation	  and	  motor	  
activity	  recording,	  they	  were	  treated	  with	  amphetamine	  (2	  mg/kg	  i.p).	  Finally,	  they	  
were	  placed	  back	  into	  the	  open	  field	  box	  with	  their	  motor	  activities	  recorded	  for	  the	  
next	  60	  minutes.	  mTOR	  inhibition	  with	  rapamycin	  resulted	  in	  significantly	  less	  
amphetamine	  induced	  motor	  activity,	  though	  no	  difference	  was	  observed	  during	  the	  
habituation	  stage	  (Figure	  6B;	  left	  panel).	  This	  result	  suggests	  that	  mTORC1	  activity	  
participates	  in	  the	  amphetamine	  induced	  motor	  response.	  We	  then	  examined	  the	  
mutant	  mice	  under	  the	  same	  paradigm	  (Figure	  6B;	  right	  panel).	  Interestingly,	  
amphetamine	  induced	  motor	  activity	  was	  dramatically	  reduced	  in	  the	  mutant	  mice	  
and	  acute	  rapamycin	  did	  not	  have	  an	  effect	  in	  these	  animals.	  The	  reduced	  effect	  of	  
amphetamine	  suggests	  that	  myc-­‐Rheb1	  (S16H)	  over-­‐expression	  blunted	  the	  
dopaminergic	  pathway	  and	  acute	  rapamycin	  treatment	  was	  not	  able	  to	  alter	  the	  
deficit.	  No	  distinguishable	  difference	  were	  observed	  when	  we	  expanded	  the	  
habituation	  studies	  by	  exposing	  mutant	  and	  control	  mice	  to	  the	  same	  open	  field	  box	  
over	  four	  sequential	  trials	  (Figure	  6C).	  Lower	  doses	  of	  amphetamine	  (0.5	  mg/kg,	  1	  
mg/kg	  i.p)	  did	  not	  show	  any	  appreciable	  differences	  between	  the	  mutant	  mice	  and	  
controls,	  thus	  substantiates	  the	  choice	  of	  2	  mg/kg	  treatment	  (Figure	  6C).	  Mutant	  
mice	  appear	  to	  have	  a	  lower	  response	  threshold	  to	  three	  consecutive	  injections	  of	  
amphetamine	  in	  comparison	  to	  control	  mice	  suggestive	  that	  the	  amphetamine	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induced	  motor	  deficit	  cannot	  be	  overcome	  with	  repeated	  stimulation	  (Figure	  6C).	  
These	  results	  suggest	  that	  mTORC1	  signaling	  contributes	  to	  the	  normal	  locomotor	  
response	  to	  amphetamine,	  and	  this	  component	  of	  the	  response	  is	  blocked	  as	  a	  
consequence	  of	  persistent	  activation	  of	  mTORC1.	  To	  the	  extent	  that	  amphetamine	  
responses	  are	  due	  to	  dopamine	  signaling,	  these	  results	  are	  consistent	  with	  the	  
notion	  that	  persistent	  mTORC1	  inhibits	  dopamine	  signaling.	  	  
Disruption	  in	  sensory	  gating	  is	  another	  characteristic	  behavior	  in	  ASD	  
involving	  movement.	  Disruptions	  in	  sensory	  gating	  are	  correlated	  with	  disruption	  of	  
prepulse	  inhibition	  (PPI)	  (Takahashi,	  Hashimoto	  et	  al.).	  The	  protocol	  we	  used	  was	  
120	  dB	  pulse	  with	  or	  without	  an	  8	  dB	  above	  background	  noise	  level	  prepulse	  with	  
recordings	  of	  startle	  reaction	  (Figure	  7A).	  Typically	  prepulse	  is	  associated	  with	  a	  
reduction	  in	  response	  amplitude	  in	  a	  normal	  behaving	  animal.	  We	  compared	  the	  
mutant	  and	  control	  mice	  throughout	  a	  range	  of	  noise	  levels	  to	  which	  they	  behaved	  
similarly	  (Figure	  7B).	  However,	  the	  mutant	  mice	  displayed	  a	  significant	  decrease	  in	  
PPI	  behavior	  as	  compared	  to	  control	  mice	  (Figure	  7B).	  To	  explore	  this	  observation	  
further,	  we	  tested	  NMDA	  receptor	  functions	  as	  previous	  studies	  have	  established	  
linkage	  between	  NMDA	  receptors	  and	  PPI	  (Lyall,	  Swanson	  et	  al.).	  Furthermore,	  
NMDA	  receptor	  functions	  are	  important	  component	  of	  synaptic	  plasticity	  and	  
genetic	  mutations	  in	  the	  NMDA	  receptor	  functional	  pathway	  have	  also	  been	  linked	  
to	  ASD	  (Tarabeux,	  Kebir	  et	  al.).	  Once	  again	  we	  employ	  the	  open	  field	  motor	  behavior	  
assay	  paradigm	  by	  substituting	  amphetamine	  with	  a	  selective	  NMDA	  receptor	  
inhibitor,	  dizocilpine	  or	  MK-­‐801	  (Figure	  7C).	  MK-­‐801	  was	  shown	  to	  induce	  motor	  
activity	  similar	  to	  that	  of	  amphetamine	  (Robbins	  and	  Murphy).	  Mice	  were	  treated	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with	  rapamycin	  or	  vehicle	  for	  40	  minutes	  followed	  by	  MK-­‐801	  with	  their	  motor	  
activity	  recorded	  throughout	  the	  study.	  Both	  the	  control	  and	  mutant	  mice	  
responded	  similarly	  to	  MK-­‐801	  and	  acute	  pretreatment	  with	  rapamycin	  did	  not	  
alter	  the	  responses	  (Figure	  7C).	  This	  suggests	  that	  mTOR	  pathway	  does	  not	  
participate	  in	  MK-­‐801	  induced	  motor	  activity	  in	  contrast	  to	  amphetamine-­‐induced	  
responses.	  Importantly,	  the	  maximal	  activity	  of	  the	  control	  and	  mutant	  mice	  was	  
very	  similar	  indicating	  that	  mutant	  mice	  are	  capable	  of	  achieving	  similar	  levels	  of	  
motor	  activity,	  thus	  further	  substantiating	  the	  differences	  in	  amphetamine	  
response.	  	  
Dopamine	  released	  from	  presynaptic	  terminal	  bind	  postsynaptic	  dopamine	  
receptors	  and	  mediates	  synaptic	  changes	  via	  signaling	  cascades.	  DAT	  clear	  
dopamine	  from	  the	  synaptic	  cleft	  and	  diminishes	  dopamine	  signaling	  overtime.	  In	  
collaboration	  with	  Dr.	  Karen	  Szumlinski	  in	  the	  Department	  of	  Psychological	  &	  Brain	  
Sciences	  at	  University	  of	  California	  Santa	  Barbara	  we	  performed	  in	  vivo	  micro-­‐
dialysis	  experiments	  to	  examine	  presynaptic	  functions	  of	  control	  and	  mutant	  mice	  
in	  response	  to	  amphetamine	  treatment.	  No	  significant	  differences	  were	  observed	  at	  
basal	  level	  and	  post	  injection	  of	  amphetamine	  in	  the	  mutant	  and	  control	  animals	  
within	  the	  time	  course	  of	  differential	  motor	  activation	  (Figure	  8A).	  Dose	  dependent	  
potassium	  depolarization	  triggering	  presynaptic	  vesicle	  fusion	  and	  
neurotransmitter	  release	  also	  did	  not	  show	  any	  appreciable	  differences	  (Figure	  8B).	  
To	  study	  the	  expression	  of	  D1R,	  D2R	  and	  DAT,	  we	  isolated	  and	  dissected	  the	  
striatum	  from	  brains	  of	  control	  and	  mutant	  mice.	  Subsequently,	  biochemical	  
fractionations	  of	  total	  homogenate,	  nuclei/large	  debris	  and	  crude	  synaptosomal	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membrane	  were	  made.	  SDS-­‐PAGE	  followed	  by	  Western	  blot	  analysis	  of	  D1R,	  D2R	  
and	  DAT	  showed	  similar	  expression	  patterns	  between	  control	  and	  mutant	  mice	  
(Figure	  8C).	  Together,	  these	  results	  suggest	  the	  preservation	  of	  presynaptic	  
integrity	  and	  function	  as	  well	  as	  postsynaptic	  receptor	  expressions	  between	  the	  
mutant	  and	  control	  animals.	  
In	  collaboration	  with	  Dr.	  David	  Linden	  and	  Dr.	  Joo	  Min	  Park	  in	  the	  
Neuroscience	  Department	  at	  Johns	  Hopkins	  School	  of	  Medicine,	  we	  examined	  
corticostriatal	  plasticity	  by	  electrophysiology	  studies	  in	  brain	  slice	  experiments.	  
This	  experimental	  setup	  takes	  advantage	  of	  cortical	  stimulation	  with	  simultaneous	  
recordings	  in	  the	  striatum	  to	  examine	  striatal	  plasticity	  (Dunnett).	  Recordings	  in	  
control	  corticostriatal	  slices	  showed	  that	  long-­‐term	  potentiation	  (LTP)	  can	  be	  
induced	  with	  high	  frequency	  stimulation	  furthermore;	  depotentiation	  can	  be	  
achieved	  with	  subsequent	  low-­‐frequency	  stimulation	  (LFS)	  (Figure	  9A).	  However,	  in	  
slices	  treated	  with	  a	  D1R	  agonist,	  SKF	  83959,	  depotentiation	  was	  attenuated	  while	  
LTP	  remained	  intact	  (Figure	  9A).	  The	  ability	  of	  SKF	  83959	  to	  selectively	  block	  
depotentiation	  suggests	  a	  substantial	  influence	  of	  D1R	  function	  on	  the	  
depotentiation	  plasticity	  in	  the	  corticostriatal	  network.	  Under	  the	  same	  
experimental	  paradigm	  with	  vehicle	  treatment	  the	  mutant	  mice	  showed	  normal	  LTP	  
induction	  and	  depotentiation	  response	  (Figure	  9B.)	  However,	  application	  of	  SKF	  
83959	  had	  minimal	  impact	  on	  depotentiation	  in	  contrast	  to	  the	  control	  slices.	  	  We	  
also	  examined	  hippocampal	  plasticity	  to	  distinguish	  between	  global	  plasticity	  
deficits	  versus	  specific	  regional	  alterations.	  We	  isolated	  hippocampal	  slices	  and	  
tested	  (R,S)-­‐Dihydroxyphenylglycine	  (DHPG)-­‐induced	  mGluR	  long-­‐term	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depotentiation	  (mGluR-­‐LTD).	  DHPG	  treatment	  induced	  indistinguishable	  mGluR-­‐
LTD	  in	  both	  control	  and	  mutant	  slices	  (Figure	  9C).	  Furthermore,	  utilizing	  Theta	  
Burst	  Stimulation	  (TBS),	  hippocampal	  slices	  derived	  from	  control	  and	  mutant	  mice	  
showed	  similar	  LTP	  induction.	  Lastly,	  High	  Frequency	  Stimulation	  (HFS),	  which	  can	  
induce	  long	  lasting	  LTP,	  was	  also	  preserved	  in	  the	  mutant	  hippocampal	  slices	  
(Figure	  9D,	  E).	  These	  data	  indicate	  that	  persistent	  up-­‐regulation	  of	  mTORC1	  results	  
in	  diminished	  post-­‐synaptic	  response	  to	  D1	  dopamine	  receptor	  activation.	  	  
To	  determine	  if	  dopamine	  receptor	  functions	  in	  the	  mutant	  animals	  remain	  
intact,	  we	  examined	  the	  dynamics	  of	  the	  signaling	  cascades	  in	  the	  striatum.	  We	  
utilized	  the	  robust	  amphetamine	  induced	  motor	  behavioral	  protocol	  followed	  by	  
immediate	  dissection	  to	  isolate	  the	  striatum	  for	  our	  examinations.	  Striatum	  lysates	  
were	  made	  followed	  by	  SDS-­‐PAGE	  and	  Western	  blot	  analysis.	  In	  striatum	  from	  
control	  animals	  we	  saw	  a	  robust	  D1R	  response	  to	  amphetamine	  treatment	  as	  
indicated	  by	  the	  increase	  of	  phosphorylation	  signals	  in	  MEK	  and	  ERK	  (Figure	  10A).	  
Interestingly,	  this	  response	  was	  inhibited	  with	  acute	  pretreatment	  with	  rapamycin.	  
Strikingly,	  in	  the	  mutant	  animals,	  p-­‐Mek	  was	  dramatically	  reduced	  at	  the	  basal	  level	  
and	  p-­‐Erk	  was	  not	  induced	  with	  amphetamine	  in	  contrast	  to	  the	  response	  in	  control	  
animals.	  Furthermore,	  acute	  treatment	  with	  Rapamycin	  had	  no	  effects	  in	  the	  mutant	  
animals.	  The	  drastic	  reduction	  in	  phospho-­‐	  Mek	  and	  Erk,	  led	  us	  to	  examine	  
phosphorylation	  of	  Dopamine-­‐	  and	  cyclic	  AMP-­‐regulated	  phosphoprotein	  32	  
(DARPP-­‐32),	  a	  key	  regulator	  of	  signaling	  in	  striatal	  neurons	  (Bateup,	  Svenningsson	  
et	  al.).	  	  In	  striatum	  from	  control	  animals	  treated	  with	  Amphetamine,	  we	  saw	  a	  
reduction	  of	  phosphorylation	  in	  p-­‐DARPP-­‐32	  (T75)	  consistent	  with	  previous	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published	  results	  (Figure	  10B)	  (Bateup,	  Svenningsson	  et	  al.).	  The	  reduction	  in	  p-­‐
DARPP-­‐32	  (T75)	  has	  been	  demonstrated	  to	  be	  due	  to	  an	  increase	  inhibition	  of	  
protein	  phosphatase	  2A	  (PP2A)	  as	  a	  result	  of	  protein	  kinase	  A	  (PKA)	  activation	  
indicating	  activation	  of	  D1R	  (Nishi,	  Snyder	  et	  al.).	  Immunoblot	  utilizing	  specific	  
antibody	  against	  phospho-­‐PP2A	  in	  striatum	  treated	  with	  Amphetamine	  showed	  a	  
decrease	  in	  phosphorylation	  indicative	  of	  an	  activated	  PP2A	  (Figure	  10B).	  Next	  we	  
examined	  the	  protein	  phosphatase	  1	  (PP1),	  a	  target	  of	  DARRP-­‐32	  (Bateup,	  
Svenningsson	  et	  al.).	  	  In	  striatum	  from	  control	  mice	  treated	  with	  amphetamine,	  we	  
saw	  a	  reduction	  in	  p-­‐PP1;	  suggestive	  that	  PP-­‐1	  phosphatase	  activity	  is	  increased	  
(Figure	  10B).	  Interestingly,	  acute	  pretreatment	  with	  rapamycin	  before	  
amphetamine	  was	  able	  to	  reverse	  the	  changes	  in	  phosphorylation	  in	  Darpp-­‐32,	  
PP2A,	  and	  PP1	  (Figure	  10B).	  In	  the	  myc-­‐Rheb1	  (S16H)	  mutant	  mice,	  neither	  
Amphetamine	  nor	  the	  acute	  pretreatment	  with	  rapamycin	  induced	  changes	  in	  the	  
phosphorylation	  status	  of	  Darpp-­‐32,	  PP2A	  and	  PP1	  (Figure	  10B).	  Furthermore,	  
PP2A	  was	  hyper-­‐phosphorylated	  and	  PP1	  was	  hypo-­‐phosphorylated	  in	  basal	  and	  
treated	  conditions.	  This	  is	  suggestive	  that	  the	  phosphatase	  activities	  of	  PP2A	  are	  
reduced	  while	  PP1	  is	  increased.	  
Examination	  of	  the	  mTOR	  pathway	  in	  response	  to	  amphetamine	  injections	  
revealed	  reduction	  in	  mTORC1	  activity	  with	  a	  concomitant	  increase	  in	  mTORC2	  
activity	  as	  indicated	  by	  p-­‐s6	  and	  p-­‐Akt	  (S473)	  respectively	  (Figure	  11).	  Since	  GSK	  
α/ß	  are	  targets	  of	  Akt,	  we	  examined	  their	  phosphorylation	  status	  (Roberts,	  Woods	  
et	  al.).	  An	  increase	  in	  phospho-­‐GSK	  α/ß	  was	  observed,	  thus	  substantiating	  the	  
increase	  in	  mTORC2	  kinase	  activity	  (Figure	  11).	  Acute	  rapamycin	  pretreatments	  led	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to	  a	  dramatic	  reduction	  in	  p-­‐Akt	  (S473)	  and	  p-­‐GSK	  α/ß.	  Curiously,	  acute	  rapamycin	  
pretreatment	  also	  led	  to	  a	  restoration	  of	  mTORC1	  activity	  as	  demonstrated	  by	  p-­‐s6	  
immunoblot	  (Figure	  11).	  In	  myc-­‐Rheb1	  (S16H)	  mutant	  mice,	  mTORC1	  activity	  was	  
consistently	  elevated	  throughout	  different	  treatment	  conditions	  (Figure	  11).	  
Moreover,	  mTORC2	  activity	  was	  consistent	  inhibited	  in	  line	  with	  previous	  studies	  
that	  persistent	  mTORC1	  activation	  leads	  to	  a	  feedback	  inhibition	  of	  mTORC2.	  These	  
disruptions	  were	  also	  observed	  in	  Nestin-­‐Cre	  mediated	  TSC2	  heterozygous	  
knockout	  animals	  (data	  not	  shown).	  	  	  
We	  sought	  to	  recapitulate	  the	  blunted	  PKA	  Map	  kinase	  signaling	  observed	  in	  
the	  myc-­‐Rheb1	  (S16H)	  mice	  in	  an	  in	  vitro	  system.	  We	  made	  neuronal	  cultures	  from	  
control	  and	  mutant	  mice	  and	  treated	  them	  with	  Brain	  Derived	  Neurotropic	  Factor	  
(BDNF).	  To	  eliminate	  mitogen,	  serum	  and	  amino	  acid	  input	  into	  the	  signaling	  
pathway,	  we	  adapted	  the	  cultures	  to	  artificial	  cerebrospinal	  fluid	  (ACSF).	  Treatment	  
with	  BDNF	  in	  control	  cultures	  activated	  Map	  kinase	  and	  mTORC1	  pathway	  in	  a	  
robust	  manner	  (Figure	  12A).	  However,	  BDNF	  treatment	  in	  mutant	  cultures	  did	  not	  
increase	  p-­‐Erk	  to	  the	  same	  extent	  as	  in	  the	  control	  cultures.	  This	  reduction	  in	  Map	  
kinase	  signaling	  was	  consistent	  with	  what	  our	  observations	  in	  the	  striatum	  of	  the	  
mutant	  mice.	  We	  over-­‐expressed	  Rheb1	  in	  HEK293	  cells	  with	  or	  without	  co-­‐
expression	  of	  Darpp-­‐32	  in	  attempt	  to	  recapitulate	  the	  PKA,	  Darpp-­‐32,	  PP1	  
deregulation	  that	  we	  previously	  observed	  in	  the	  in	  vivo	  experiments.	  Rheb1	  over	  
expression	  increased	  mTORC1	  activity	  as	  demonstrated	  by	  p-­‐s6	  (Figure	  12B).	  
Treatment	  with	  Epidermal	  Growth	  Factor	  (EGF)	  increased	  mTORC1	  activity	  in	  cells	  
without	  Rheb1	  over-­‐expression	  but	  did	  not	  further	  increase	  mTORC1	  activity	  in	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Rheb1	  over-­‐expressing	  cells.	  Rheb1	  over-­‐expression	  also	  prevented	  EGF	  induced	  p-­‐
Erk.	  Basal	  p-­‐Darpp-­‐32	  was	  not	  altered	  with	  over-­‐expression	  of	  Rheb1	  (S16H)	  or	  
wild	  type	  Rheb1,	  however	  addition	  of	  EGF	  led	  to	  the	  reduction	  Darpp-­‐32	  
phosphorylation.	  Interestingly	  p–Darpp-­‐32	  reduction	  by	  addition	  of	  EGF	  was	  
prevented	  in	  Rheb1	  over-­‐expressing	  cells,	  similar	  to	  the	  in	  vivo	  experiments.	  
Furthermore,	  with	  Darpp-­‐32	  expression	  alone	  led	  to	  the	  phosphorylation	  of	  PP1	  but	  
not	  in	  cells	  co-­‐expressing	  Rheb1	  and	  addition	  of	  EGF	  (Figure	  12B).	  These	  results	  
indicate	  that	  chronic	  mTORC1	  activation	  by	  over-­‐expression	  of	  Rheb1	  inhibits	  
phosphorylation	  of	  Erk	  in	  response	  to	  stimuli,	  such	  as	  EGF.	  Chronic	  mTORC1	  
activation	  by	  over-­‐expression	  of	  Rheb1	  also	  prevents	  the	  phosphorylation	  and	  
inhibition	  of	  PP1	  in	  basal	  state	  and	  in	  response	  to	  stimuli.	  Thus	  persistent	  mTORC1	  





Persistent	  elevation	  in	  mTOR	  signaling	  leads	  to	  detrimental	  diseases	  and	  
disruption	  of	  homeostasis	  due	  to	  the	  involvement	  of	  mTOR	  in	  multiple	  fundamental	  
cellular	  processes	  (Hoeffer	  and	  Klann).	  One	  well-­‐characterized	  study	  of	  the	  
pathological	  result	  in	  chronic	  elevation	  of	  mTOR	  signaling	  pathway	  is	  in	  diabetes,	  
where	  a	  feedback	  inhibition	  of	  insulin	  receptor	  signaling	  pathway	  occurs	  as	  a	  
consequence	  of	  persistent	  elevation	  of	  mTOR	  (Zoncu,	  Bar-­‐Peled	  et	  al.).	  In	  this	  study,	  
with	  the	  generation	  of	  the	  mutant	  mice	  lacking	  Rheb1	  in	  the	  brain,	  we	  demonstrated	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Rheb1	  is	  essential	  for	  mTORC1	  activity	  but	  not	  mTORC2.	  Furthermore,	  mTORC2	  
activity	  is	  elevated	  due	  to	  the	  relief	  of	  feedback	  inhibition	  from	  mTORC1	  activity.	  
This	  is	  the	  first	  in	  vivo	  demonstration	  of	  the	  regulation	  and	  is	  consistent	  with	  
previous	  research	  results	  (Sarbassov,	  Guertin	  et	  al.).	  	  
We	  found	  that	  mice	  with	  brain	  specific	  over-­‐expression	  of	  myc-­‐Rheb1	  (S16H)	  
revealed	  ASD-­‐like	  behaviors	  through	  social	  investigation	  behavioral	  experiments	  
and	  PPI	  examination.	  The	  ASD-­‐like	  behaviors	  were	  relatively	  specific	  as	  no	  
appreciable	  differences	  were	  observed	  in	  other	  general	  behavioral	  tasks	  in	  
comparison	  to	  control	  mice.	  These	  ASD-­‐	  like	  behaviors	  have	  also	  been	  observed	  in	  
mouse	  models	  of	  TSC	  and	  Pten	  (Tsai,	  Hull	  et	  al.)	  (Kwon,	  Luikart	  et	  al.).	  These	  mouse	  
models	  all	  share	  persistent	  increase	  in	  mTORC1	  activity	  suggesting	  that	  sustained	  
mTORC1	  activity	  as	  a	  strong	  casual	  link	  to	  ASD-­‐like	  behaviors.	  Furthermore,	  
disruption	  of	  the	  ability	  of	  mTORC1	  to	  integrate	  changes	  experienced	  by	  the	  
neurons	  leads	  to	  devastating	  outcomes	  for	  the	  neural	  circuitry	  and	  animal.	  	  
To	  find	  the	  causality	  of	  the	  social	  motivation	  deficits,	  we	  examined	  the	  
striatum	  since	  it	  is	  involved	  in	  social	  motivation	  and	  reward	  integration.	  First,	  we	  
established	  that	  mTOR	  pathway	  contributes	  to	  amphetamine	  induced	  motor	  
activation	  behavior	  with	  rapamycin	  injection	  in	  the	  control	  mice.	  Mutant	  mice	  over-­‐
expressing	  myc-­‐Rheb1	  (S16H)	  showed	  a	  drastic	  reduction	  in	  amphetamine	  induced	  
motor	  activation	  and	  in	  contrast	  to	  control	  mice,	  acute	  pretreatment	  with	  
rapamycin	  had	  no	  effect.	  These	  results	  suggested	  two	  potential	  deficits	  in	  the	  
mutants;	  D1R	  activation	  (striatonigral	  pathway)	  is	  disrupted	  or	  D2R	  (striatopallidal	  
pathway)	  is	  persistently.	  Micro-­‐dialysis	  experiments	  measuring	  synaptic	  dopamine	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levels	  and	  dopamine	  vesicle	  release	  showed	  no	  significant	  changes	  between	  the	  
mutant	  and	  control	  mice.	  Moreover,	  we	  did	  not	  detect	  any	  significant	  changes	  in	  
D1R,	  D2R	  and	  DAT	  expression.	  Thus,	  led	  us	  to	  focus	  on	  examining	  the	  functions	  of	  
D1R	  and	  D2R.	  Electrophysiology	  studies	  suggested	  that	  striatum	  plasticity	  
disruptions	  were	  rather	  selective	  since	  depotentiation	  experiments	  in	  corticostriatal	  
slices	  with	  D1R	  agonist	  showed	  that	  the	  mutant	  mice	  were	  not	  sensitive	  to	  D1R	  
activation.	  Meanwhile,	  hippocampal	  plasticity	  remained	  intact.	  Moreover,	  
biochemical	  analyses	  from	  the	  brains	  of	  mutant	  mice	  treated	  with	  different	  
combinations	  of	  rapamycin	  and	  amphetamine	  revealed	  that	  PKA,	  p-­‐Mek	  and	  mTOR	  
pathways	  were	  not	  sensitive	  to	  stimulation	  and	  modulation.	  Furthermore,	  Darpp32	  
phosphorylation	  was	  uncoupled	  amphetamine	  induced	  regulations.	  Since	  we	  have	  
established	  that	  expression	  of	  D1R	  was	  comparable	  between	  mutant	  and	  control	  
animals,	  this	  result	  was	  intriguing,	  as	  it	  suggested	  that	  D1R	  function	  might	  be	  
disrupted.	  D1R	  engages	  PKA	  pathway,	  which	  in	  turn	  contribute	  to	  the	  trafficking	  of	  
AMPAR	  and	  NMDAR,	  which	  underlie	  synaptic	  plasticity	  responses.	  Moreover,	  PKA	  
can	  also	  modulate	  voltage	  dependent	  ion	  channels	  that	  contribute	  to	  NMDAR	  
function	  (Skeberdis,	  Chevaleyre	  et	  al.).	  Thus,	  disruption	  of	  the	  D1R	  signaling	  
pathway	  would	  alter	  depotentiation	  plasticity	  in	  the	  corticostriatal	  network.	  
Autism	  Spectrum	  Disorders	  (ASDs)	  are	  a	  group	  of	  clinically	  and	  genetically	  
heterogeneous	  neurodevelopment	  disorders	  characterized	  by	  impaired	  social	  
interaction,	  repetitive	  behaviors,	  and	  restricted	  interests	  (Baird,	  Dewar	  et	  al.)	  
(Zoghbi	  and	  Bear).	  Recent	  genetic	  studies	  have	  demonstrated	  that	  Pten	  and	  Tsc	  
mutations	  result	  in	  persistent	  increase	  of	  mTOR	  signaling	  and	  contribute	  to	  ASDs	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(Zoghbi	  and	  Bear).	  It	  is	  estimated	  that	  TSC1	  mutations	  account	  for	  30%	  familial	  
cases	  and	  15%	  sporadic	  causes	  while	  TSC2	  accounts	  for	  50%	  sporadic	  causes	  of	  ASD	  
or	  Tuberous	  sclerosis	  (Zoghbi	  and	  Bear).	  In	  consideration	  of	  the	  social	  behavior	  
deficits	  and	  repetitive	  behaviors,	  investigators	  have	  examined	  the	  basal	  ganglia,	  
specifically	  striatum.	  Studies	  utilizing	  PET	  and	  MRI	  have	  shown	  deficits	  in	  striatum	  
functions	  in	  patients	  with	  ASD	  (Duchesnay,	  Cachia	  et	  al.)	  (Gaetz,	  Bloy	  et	  al.).	  
Striatum	  acts	  as	  an	  information	  integrator	  in	  the	  brain	  receiving	  sensory	  modalities;	  
context,	  planning	  and	  memory	  inputs	  from	  different	  parts	  of	  the	  brain	  and	  outputs	  
control	  motor	  activity,	  executive	  function	  and	  reinforce	  reward	  learning.	  Striatum	  is	  
mostly	  composed	  of	  Gabaergic	  medium	  spiny	  neurons	  that	  receive	  glutamatergic	  
inputs	  from	  the	  cortex,	  amygdala,	  hippocampus	  and	  thalamus	  (Shepherd)	  (Figure	  
2A).	  The	  striatum	  projects	  in	  two	  output	  pathways.	  The	  striatonigral	  pathway,	  also	  
known	  as	  the	  direct	  pathway,	  is	  distinguished	  by	  coupling	  to	  Dopamine	  receptor	  1	  
(D1R),	  while	  the	  Striatopallidal	  or	  indirect	  pathway	  is	  identified	  by	  the	  coupling	  to	  
Dopamine	  receptor	  2	  (D2R).	  In	  a	  simplified	  representation,	  D1	  pathway	  is	  also	  
known	  as	  “go”	  pathway,	  whereas	  D2	  pathway	  is	  the	  “no-­‐go”	  pathway	  in	  terms	  of	  
motor	  activity.	  (Figure	  2B).	  D1R	  and	  D2R	  pathways	  have	  opposing	  actions	  on	  
complex	  signal	  transduction	  cascade	  networks	  composed	  of	  multiple	  inputs	  and	  
outputs	  (Beaulieu,	  Gainetdinov	  et	  al.)	  (Figure	  3).	  
We	  characterized	  mTORC1	  and	  mTORC2	  signaling	  activities	  in	  the	  striatum	  
and	  found	  that	  mice	  with	  brain	  specific	  over-­‐expression	  of	  myc-­‐Rheb1	  (S16H)	  
displayed	  persistent	  elevation	  of	  mTORC1	  activity	  supportive	  of	  the	  notion	  that	  
Rheb1	  is	  critical	  for	  mTORC1	  function.	  Furthermore,	  mTORC2	  activity	  is	  decreased	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in	  the	  brains	  of	  these	  animal,	  substantiating	  the	  feedback	  inhibition	  regulation	  is	  
increased	  as	  a	  result	  of	  increased	  mTORC1	  activity.	  	  The	  feedback	  inhibition	  also	  
impacted	  the	  dynamics	  of	  D1R	  and	  D2R	  mediated	  signaling	  in	  the	  striatum	  from	  
mutant	  mice.	  In	  the	  mutant	  mice	  the	  ability	  for	  mTOR	  signaling	  pathway	  to	  integrate	  
changes	  due	  to	  intra-­‐	  and	  extra-­‐	  cellular	  environment	  was	  disrupted.	  
In	  conclusion,	  our	  results	  suggest	  that	  persistent	  mTORC1	  activity	  down	  
regulates	  G-­‐protein	  signaling	  and	  reward	  pathway	  in	  the	  striatum.	  The	  loss	  of	  
integration	  function	  by	  mTOR	  pathway	  in	  the	  striatum,	  which	  serves	  as	  an	  
integrator	  for	  the	  central	  nervous	  system,	  can	  lead	  to	  devastating	  disorders	  such	  as	  
ASD.	  Furthermore,	  myc-­‐Rheb1	  (S16H)	  over-­‐expression	  in	  the	  brain	  is	  both	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CHAPTER	  4:	  





Cellular	  signaling	  pathways	  have	  evolved	  to	  facilitate	  cells’	  ability	  to	  adapt	  to	  
constant	  changes	  of	  intracellular	  and	  extracellular	  environments.	  The	  complex	  post-­‐
translational	  protein-­‐modification	  signaling	  cascades	  underlie	  the	  output	  function	  
by	  cells	  to	  ensure	  survival	  and	  proper	  function.	  	  Cellular	  signaling	  relies	  on	  many	  
components	  of	  the	  trafficking	  machinery.	  Endosomes	  are	  membrane	  inclusion	  
vehicles	  that	  transport	  proteins	  and	  macromolecules	  inside	  cells.	  Maturation	  and	  
trafficking	  of	  endosomes	  have	  been	  under	  intensive	  study,	  which	  yielded	  
identification	  of	  protein	  markers	  that	  can	  be	  utilized	  to	  track	  their	  status	  and	  
function	  (Palfy,	  Remenyi	  et	  al.).	  In	  neurons,	  endosomes	  are	  the	  membrane	  vehicles	  
that	  aid	  receptor	  recycling	  or	  initiate	  protein	  degradation	  pathways.	  	  Biomarkers	  
such	  as	  the	  members	  of	  the	  small	  GTPase	  family,	  Rabs,	  are	  often	  used	  to	  identify	  
maturation	  stages	  of	  endosomes.	  Endosomes	  are	  categorized	  into	  three	  
compartments,	  which	  suggest	  their	  maturation	  status.	  Rab4	  identifies	  early	  
endosomes,	  Rab7	  identifies	  late	  endosomes	  and	  Rab11	  have	  been	  identified	  to	  
associate	  with	  recycling	  endosomes	  (Huotari	  and	  Helenius).	  Since	  endosomes	  are	  
lipid	  membrane	  entities	  that	  contain	  phosphatidylinositol	  (PtdIns)	  moieties,	  protein	  
kinases	  that	  modify	  PtdIns	  are	  often	  found	  to	  regulate	  and	  associate	  with	  
endosomes.	  One	  major	  class	  of	  protein	  kinases	  that	  modify	  PtdIns	  is	  the	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Phosphatidylinositidies	  3-­‐	  kinase	  family	  (PI3Ks).	  PI3Ks	  are	  a	  family	  of	  enzymes	  that	  
phosphorylates	  the	  3	  position	  hydroxyl	  group	  of	  the	  inositol	  ring	  of	  PdtIns	  and	  thus	  
act	  as	  signaling	  transducers	  (Murphy,	  Padilla	  et	  al.).	  	  
PI	  3-­‐kinases	  have	  been	  demonstrated	  to	  participate	  in	  mechanisms	  
facilitating	  learning	  and	  memory	  and	  specifically	  glutamate	  receptor	  trafficking	  
(Kim,	  Lee	  et	  al.).	  PI3K	  and	  mammalian	  Target	  of	  Rapamycin	  (mTOR)	  belong	  to	  the	  PI	  
3-­‐kinase	  superfamily.	  PI3K-­‐mTOR	  signaling	  pathway	  mediates	  cellular	  functions	  to	  
ensure	  proper	  proliferation	  and	  survival	  (Laplante	  and	  Sabatini).	  Aberrant	  PI3K-­‐
mTOR	  signaling	  leads	  to	  detrimental	  outcome	  for	  the	  cell	  and	  organism	  (Laplante	  
and	  Sabatini).	  In	  response	  to	  extra-­‐	  and	  intra-­‐	  cellular	  environmental	  changes,	  
mTOR	  signaling	  pathway	  regulates	  protein	  translation,	  protein	  turnover,	  cellular	  
skeletal	  remodeling,	  lipid	  biosynthesis	  and	  transcriptional	  changes	  (Sarbassov,	  Ali	  
et	  al.).	  Recent	  immunocytochemistry	  studies	  by	  investigators	  demonstrated	  that	  
active	  mTOR	  associates	  with	  late	  endosomes/lysosomes	  and	  is	  dependent	  on	  amino	  
acid	  availability	  (Sancak,	  Peterson	  et	  al.).	  Furthermore,	  mTOR	  kinase	  activity	  was	  
found	  to	  be	  dependent	  on	  functional	  V-­‐ATPase	  ion	  pump	  that	  acidifies	  the	  lumen	  of	  
the	  endosomes	  as	  it	  matures	  from	  early	  to	  late	  endosomes.	  Further	  characterization	  
studies	  revealed	  that	  Rag	  GTPases	  were	  the	  mediators	  of	  mTOR	  activity	  and	  V-­‐
ATPase	  function	  by	  conjugating	  mTOR	  to	  the	  lysosome	  (Zoncu,	  Bar-­‐Peled	  et	  al.).	  
However,	  the	  contribution	  of	  Rheb1	  to	  mTOR	  activation	  remains	  elusive.	  Previous	  
studies	  have	  demonstrated	  that	  Rheb1	  is	  essential	  for	  mTOR	  complex	  1	  (mTORC1)	  
activation	  (Zou,	  Zhou	  et	  al.).	  We	  sought	  to	  identify	  the	  molecular	  and	  cellular	  basis	  
of	  Rheb1-­‐dependent	  activation	  of	  mTORC1	  in	  neurons.	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Results	  
To	  study	  the	  localization	  of	  the	  protein	  components	  of	  the	  mTOR	  pathway	  we	  
made	  biochemical	  sub-­‐cellular	  fractions	  from	  forebrains	  of	  Wild	  Type	  (WT)	  mouse	  
at	  the	  age	  of	  postnatal	  30	  days	  (Figure	  1A,	  1B).	  Treatment	  with	  different	  density	  of	  
sucrose	  and	  sequences	  of	  centrifugation	  allows	  sub-­‐cellular	  compartments	  to	  be	  
isolated,	  including	  total	  homogenate	  (H),	  nuclei/large	  debris	  (P1),	  crude	  
synaptosomal	  membrane	  (P2),	  light	  membrane	  (P3),	  synaptosomal	  membrane	  
(LP1)	  and	  synaptic	  vesicle	  enriched	  fraction	  (LP2)	  (Hallett,	  Collins	  et	  al.).	  Western	  
blot	  analysis	  shows	  that	  Rheb1	  is	  significantly	  enriched	  in	  the	  LP2	  fraction	  
coinciding	  with	  the	  most	  significant	  p-­‐mTOR	  signal	  (Figure	  1B).	  This	  finding	  is	  
consistent	  with	  previous	  finding	  that	  Rheb1	  is	  necessary	  for	  mTOR	  activation	  (Zou,	  
Zhou	  et	  al.).	  Furthermore,	  we	  observed	  other	  components	  of	  the	  mTORC1	  pathway	  
way	  such	  as	  TSC2	  and	  s6	  in	  the	  LP2	  fraction.	  Early	  and	  late	  endosomes	  
demonstrated	  by	  Rab4	  and	  Rab7	  immunoblots,	  indicate	  that	  we	  were	  able	  to	  isolate	  
synaptic	  trafficking	  vehicles	  in	  the	  LP2	  fraction.	  Utilizing	  specific	  antibodies	  against	  
Shank3,	  we	  show	  that	  the	  biochemical	  fractions	  are	  specific	  as	  Shank3	  is	  only	  
enriched	  in	  the	  LP1	  and	  P3	  fractions.	  GluR1,	  GluR2,	  NR1	  and	  NR2A	  immunoblots	  
also	  demonstrate	  specific	  enrichment	  of	  the	  glutamate	  receptors	  at	  the	  LP1	  fraction.	  
Consistent	  with	  previous	  reports,	  only	  GluR2	  and	  NR1	  but	  not	  GluR1	  or	  NR2A	  are	  
observed	  in	  the	  LP2	  fractions	  (Hallett,	  Collins	  et	  al.).	  We	  also	  employed	  continuous	  
sucrose	  density	  gradient	  centrifugation	  technique	  and	  identify	  the	  association	  of	  
Rheb1	  with	  vesicle-­‐enriched	  fractions.	  Isolated	  fractions	  were	  subjected	  to	  SDS-­‐
PAGE	  and	  Rheb1	  was	  visualized	  by	  Western	  blot	  analysis	  utilizing	  specific	  Rheb1	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antibody	  (Figure	  1C).	  Rheb1	  signals	  were	  observed	  in	  fractions	  10,	  11,	  and	  12	  
containing	  large	  protein	  complexes	  and	  vesicles	  such	  as	  endosomes,	  lysosomes,	  and	  
multi-­‐vesicular	  bodies.	  Observations	  of	  Rheb1	  in	  fraction	  1-­‐6	  may	  be	  due	  to	  the	  
disruptive	  nature	  of	  centrifugation	  force	  or	  the	  existence	  of	  Rheb1	  in	  smaller	  
protein	  complexes.	  	  
In	  order	  to	  gain	  insight	  on	  how	  Rheb1	  might	  contribute	  to	  mTOR	  activity	  we	  
sought	  to	  identify	  proteins	  that	  associate	  with	  Rheb1.	  We	  employed	  the	  Nestin-­‐Cre	  
mediated	  expression	  of	  Myc-­‐Rheb1	  (S16H)	  mouse	  model	  (Mutant)	  for	  our	  
biochemical	  assays.	  Myc	  epitope	  allows	  for	  specific	  immunoprecipitation	  (IP)	  of	  
myc-­‐Rheb1	  since	  no	  specific	  antibodies	  against	  endogenous	  Rheb1	  are	  available	  at	  
the	  present	  time.	  Substitution	  of	  Rheb1	  at	  Serine	  16	  with	  Histidine	  (S16H)	  makes	  it	  
resistant	  to	  the	  inhibition	  of	  Tuberous	  Sclerosis	  Complex	  (TSC)	  thus	  yielding	  a	  more	  
competent	  Rheb1	  to	  activate	  mTORC1	  (Yan,	  Findlay	  et	  al.).	  	  
Taking	  advantage	  of	  the	  knowledge	  that	  farnesylation	  of	  Rheb1	  is	  required	  
for	  its	  membrane	  association	  and	  function,	  we	  made	  forebrain	  lysates	  with	  ice	  cold	  
1%	  Triton-­‐X	  100	  buffer	  from	  Postnatal	  (P)30	  control	  and	  mutant	  mice	  (Yamagata,	  
Sanders	  et	  al.).	  Ice	  cold	  1%	  Triton-­‐X	  100	  buffer	  lysis	  treatment	  is	  relatively	  non-­‐
denaturing	  thus	  preserves	  selective	  membrane	  association	  and	  integrity.	  SDS-­‐PAGE	  
followed	  by	  silver	  staining	  visualization	  procedures	  showed	  that	  anti-­‐myc	  IP	  from	  
mutants	  had	  a	  dramatic	  enrichment	  of	  proteins	  associated	  with	  Myc-­‐Rheb1	  
compared	  to	  the	  anti-­‐Myc	  IP	  in	  control	  brains	  (Figure	  2A).	  More	  efficient	  elution	  of	  
associated	  proteins	  were	  achieved	  with	  the	  addition	  Beta-­‐MercaptoEthanol	  in	  the	  
presence	  of	  4%	  SDS	  in	  anti-­‐myc	  IP	  from	  the	  mutant	  brains	  while	  no	  significant	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difference	  was	  observed	  in	  the	  control	  IPs.	  “Lysates	  after	  IP”	  lane	  shows	  similar	  
protein	  band	  pattern	  as	  “lysate	  input”	  lane	  demonstrates	  that	  protein	  integrity	  was	  
preserved	  during	  the	  IP	  procedure.	  Next,	  we	  compared	  the	  same	  IP	  procedure	  in	  
control	  and	  mutant	  forebrains	  prepared	  in	  RIPA	  with	  0.1%	  SDS	  buffer.	  RIPA	  with	  
1%	  SDS	  buffer	  is	  a	  relatively	  stringent	  condition	  to	  examine	  protein	  associations	  
(Figure	  2B).	  SDS-­‐PAGE	  followed	  by	  silver	  staining	  showed	  significant	  less	  
association	  of	  proteins	  in	  the	  anti-­‐myc	  IP	  compared	  with	  anti-­‐myc	  IP	  in	  1%	  Trition-­‐
X	  100	  buffer	  condition.	  Furthermore,	  only	  a	  few	  protein	  band	  signals	  were	  observed	  
in	  the	  anti-­‐myc	  IP	  sample	  from	  mutant	  brains	  while	  no	  significant	  protein	  band	  
signals	  were	  detected	  in	  the	  anti-­‐myc	  IP	  sample	  from	  control	  brains.	  We	  then	  
examined	  anti-­‐myc	  IPs	  from	  mutant	  and	  control	  brains	  for	  association	  with	  
membranes	  by	  confocal	  microscopy.	  We	  treated	  the	  magnetic	  beads	  with	  a	  different	  
myc	  antibody	  conjugated	  with	  Alexa-­‐555	  fluorophore	  to	  allow	  for	  visualization	  
(Figure	  2C).	  With	  1%	  Triton-­‐X	  100	  lysis	  condition,	  anti-­‐myc	  IP	  from	  mutant	  brains	  
showed	  large	  clusters	  of	  fluorescence	  where	  as	  anti-­‐myc	  IP	  from	  control	  brains	  
were	  void	  fluorescent	  signal.	  The	  fluorescent	  signal	  difference	  was	  consistent	  with	  
the	  biochemical	  results	  found	  with	  SDS-­‐PAGE	  and	  silver	  staining	  suggesting	  that	  1%	  
Triton-­‐X	  100	  lysis	  treatment	  preserves	  association	  of	  myc-­‐Rheb1	  (S16H)	  with	  
membranes	  and	  proteins.	  To	  identify	  proteins	  that	  associate	  with	  myc-­‐Rheb1	  
(S16H)	  we	  provided	  elutions	  from	  anti-­‐myc	  IPs	  to	  the	  Taplin	  Mass	  Spectrometry	  
Facility	  at	  Harvard	  University	  for	  Liquid	  Chromatography-­‐tandem	  mass	  
spectrometry	  method	  (LC/MS/MS)	  analysis.	  We	  compared	  anti-­‐myc	  IP	  samples	  
from	  1%	  Triton-­‐X	  100	  with	  anti-­‐myc	  IP	  samples	  from	  RIPA	  with	  0.1%	  SDS	  (Figure	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3A).	  Interestingly,	  proteins	  identified	  in	  1%	  Triton-­‐X	  100	  are	  enriched	  with	  
receptors,	  ion	  channels,	  synaptic	  proteins,	  ubiquitinylating	  proteins	  and	  vesicle	  
associated	  proteins.	  Moreover,	  subunits	  of	  lysosomal	  H+	  ATPase	  were	  identified	  by	  
LC/MS/MS	  analysis.	  This	  finding	  is	  consistent	  with	  previously	  published	  results	  that	  
demonstrated	  Rheb1	  associates	  with	  lysosomes	  to	  facilitate	  mTOR	  kinase	  activation	  
(Zoncu,	  Bar-­‐Peled	  et	  al.).	  Furthermore,	  the	  transmembrane	  proteins	  including	  GluR2	  
and	  other	  ion	  channels	  suggest	  that	  myc-­‐Rheb1	  (S16H)	  associates	  with	  trafficking	  
endosomes	  possibly	  throughout	  endosome	  maturation	  process.	  It	  is	  also	  worth	  to	  
note	  that	  kinases	  and	  phosphatases	  involved	  in	  signaling	  cascade	  such	  as	  protein	  
phosphatase	  -­‐1,	  -­‐2	  and	  calcium/calmodulin-­‐dependent	  kinase	  II	  were	  also	  found	  to	  
associate	  with	  myc-­‐Rheb1	  (S16H).	  LC/MS/MS	  analysis	  of	  elution	  samples	  from	  myc-­‐
Rheb1	  (S16H)	  IP	  in	  RIPA	  with	  0.1%	  SDS	  buffer	  yielded	  much	  less	  proteins	  (Figure	  
3B).	  This	  is	  likely	  due	  to	  the	  stringent	  and	  denaturing	  conditions	  of	  RIPA	  buffer	  with	  
the	  addition	  of	  SDS.	  Proteins	  identified	  with	  this	  method	  are	  likely	  to	  be	  more	  stably	  
associated	  or	  interact	  directly	  with	  Myc-­‐Rheb1	  (S16H).	  Interestingly,	  the	  list	  of	  
proteins	  from	  two	  different	  anti-­‐myc	  IP	  conditions	  did	  not	  overlap.	  It	  is	  worth	  to	  
note	  that	  Rheb1	  was	  the	  identified	  by	  LC/MS/MS	  in	  both	  IP	  methods	  and	  that	  the	  
lists	  of	  proteins	  identified	  are	  not	  comprehensive.	  Encouraged	  by	  the	  LC/MS/MS	  
data,	  we	  sought	  to	  identify	  other	  potential	  proteins	  associated	  with	  myc-­‐Rheb1	  with	  
1%	  Trition-­‐X	  100	  lysis	  by	  Western	  blot	  analysis	  (Figure	  4).	  Rheb1	  immunoblot	  
shows	  endogenous	  Rheb1	  in	  both	  control	  and	  myc-­‐Rheb1	  (S16H)	  inputs.	  Myc-­‐
Rheb1	  (S16H)	  showed	  an	  increase	  in	  molecular	  weight	  due	  to	  the	  myc	  epitope	  tag	  
and	  was	  only	  identified	  in	  the	  myc-­‐Rheb1	  (S16H)	  lane	  as	  indicated.	  Furthermore,	  we	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confirmed	  that	  myc-­‐Rheb1	  (S16H)	  was	  successfully	  enriched	  in	  our	  anti-­‐myc	  IP	  
(Figure	  4A).	  Utilizing	  specific	  antibodies	  in	  multiple	  Western	  blot	  analysis	  we	  found	  
that	  association	  of	  myc-­‐Rheb1	  (S16H)	  with	  GluR2,	  GluR4,	  Grip,	  NR1,	  mGluR5,	  
Homer,	  Arc,	  Shank3	  and	  various	  forms	  of	  APP	  (Figure	  4B).	  Most	  of	  these	  proteins	  
are	  localize	  to	  the	  synapse	  and	  participates	  in	  synaptic	  plasticity.	  However,	  these	  
interactions	  are	  rather	  specific	  since	  not	  all	  synaptic	  proteins	  or	  membrane-­‐
associated	  proteins	  were	  found	  to	  interact	  with	  myc-­‐Rheb1	  (S16H)	  (Figure	  4C).	  
Moreover,	  we	  did	  not	  find	  components	  of	  the	  mTOR	  pathway	  to	  associate	  with	  the	  
myc-­‐Rheb1	  (S16H).	  No	  significant	  signals	  were	  detected	  in	  immunoblots	  using	  
specific	  antibodies	  for	  Rag	  GTPases,	  mTOR	  (Figure	  4C)	  or	  TSC2	  (data	  not	  shown).	  
We	  did	  not	  find	  GluR1	  to	  associate	  with	  the	  myc-­‐Rheb1	  (S16H)	  which	  parallels	  the	  
findings	  in	  the	  sub-­‐cellular	  fractionation	  experiment	  that	  GluR1	  was	  not	  
significantly	  enriched	  in	  the	  LP2	  fraction	  (Figure	  1B).	  Intrigued	  by	  the	  LC/MS/MS	  
finding	  that	  myc-­‐Rheb1	  (S16H)	  associated	  with	  ubiquitin	  modification	  proteins	  and	  
components	  of	  the	  degradation	  machinery	  such	  as	  lysosome	  and	  ubiquitin,	  we	  
examined	  the	  anti-­‐myc	  IP	  for	  enrichment	  of	  ubiquitinylated	  proteins.	  Ponceau	  
staining	  of	  input	  lysate	  to	  anti-­‐myc	  IP	  showed	  anti-­‐myc	  IP	  yielded	  significantly	  less	  
proteins	  as	  demonstrated	  by	  the	  reduced	  staining	  compared	  with	  input	  (Figure	  4D).	  
However,	  using	  a	  specific	  polyubiquitin	  antibody,	  Fk1,	  we	  observed	  that	  anti-­‐myc	  IP	  
enriched	  for	  polyubiquitinylated	  proteins	  in	  comparison	  to	  input.	  This	  result	  
suggested	  that	  proteins	  associated	  with	  myc-­‐Rheb1	  (S16H)	  enriched	  for	  proteins	  
destined	  for	  degradation	  via	  proteosome	  as	  well	  as	  lysosome	  pathways.	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Previous	  studies	  have	  demonstrated	  that	  growth	  factors	  in	  serum	  and	  amino	  
acids	  can	  stimulate	  mTORC1	  kinase	  activity	  (Nobukuni,	  Joaquin	  et	  al.).	  We	  employed	  
Human	  Embryonic	  Kidney	  293	  (HEK293)	  cells	  for	  mTORC1	  functional	  studies.	  We	  
depleted	  serum	  and	  amino	  acids	  by	  adapting	  HEK293	  cells	  in	  Hank’s	  Balanced	  Salt	  
Solution	  (HBSS)	  for	  2	  h,	  which	  reduced	  mTORC1	  activity	  to	  baseline	  demonstrated	  
by	  p-­‐s6	  immunoblotting.	  With	  the	  addition	  of	  serum	  or	  amino	  acid	  for	  20	  minutes	  
we	  were	  able	  to	  increased	  mTORC1	  activity	  significantly.	  Following	  our	  observation	  
that	  myc-­‐Rheb1	  (S16H)	  associated	  with	  ubiquitinylated	  proteins	  destined	  for	  
proteosome	  processing,	  we	  tested	  whether	  inhibition	  of	  proteosome	  would	  reduce	  
mTORC1	  activity.	  Treatment	  with	  proteosome	  inhibitor,	  MG132	  for	  2	  h	  in	  DIV-­‐17	  
dissociated	  cortical	  neuron	  cultures	  derived	  from	  control	  or	  myc-­‐Rheb1	  (S16H)	  
mice	  reduced	  mTORC1	  activity	  (Figure	  5B).	  Treatment	  with	  vehicle	  or	  MG132	  did	  
not	  alter	  MAP-­‐kinase	  signaling	  shown	  by	  p-­‐Erk	  immunoblot.	  It	  is	  worth	  to	  note	  that	  
despite	  of	  the	  elevated	  mTORC1	  activity	  in	  the	  myc-­‐Rheb1	  (S16H)	  over-­‐expressing	  
neurons	  cultures,	  MG132	  was	  still	  able	  to	  reduce	  mTORC1	  activity.	  Combining	  the	  
results	  that	  amino	  acid	  stimulates	  mTORC1	  activity	  and	  proteosome	  inhibition	  
reduces	  mTORC1	  activity,	  our	  finding	  suggest	  that	  amino	  acids	  generated	  from	  
proteosome	  processing	  of	  proteins	  facilitate	  mTORC1	  function.	  Next	  we	  tested	  
whether	  inhibition	  of	  group	  1	  metabotropic	  receptors	  would	  alter	  mTORC1	  
signaling	  due	  to	  the	  observation	  that	  myc-­‐Rheb1	  (S16H)	  associates	  with	  mGluR5.	  
Addition	  of	  Bay	  36-­‐7620	  (an	  inverse	  agonist	  of	  mGluR1)	  and	  MPEP	  (a	  mGluR5	  
antagonist)	  for	  2	  h	  in	  DIV-­‐17	  dissociated	  cortical	  neuron	  cultures	  dramatically	  
reduced	  mTORC1	  activity	  (Figure	  5B).	  Map-­‐Kinase	  signaling	  pathway	  reductions	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were	  observed	  in	  contrast	  to	  MG132	  treatment	  demonstrated	  by	  p-­‐Erk	  immunoblot.	  
Consistent	  with	  dissociated	  cortical	  neuron	  culture	  experiments,	  intraperitoneal	  
injection	  of	  AIDA,	  an	  mGluR1	  antagonist	  and	  MPEP	  in	  P40	  control	  mice	  also	  reduced	  
both	  mTORC1	  and	  MAP-­‐kinase	  activity	  (Figure	  5C).	  The	  reduction	  of	  mTORC1	  
activity	  was	  further	  substantiated	  by	  the	  observation	  that	  p-­‐TSC2	  was	  increased	  
upon	  treatment	  with	  AIDA	  and	  MPEP,	  most	  likely	  due	  to	  the	  feedback	  regulation	  of	  
mTORC1	  to	  mTORC2.	  	  
	  
Discussion	  	  
Our	  results	  suggest	  a	  model	  where	  Rheb1	  is	  enriched	  in	  endosomal-­‐like	  
trafficking	  vesicles	  and	  associates	  proteins	  that	  are	  destined	  for	  degradation	  
processes.	  The	  turn	  over	  of	  proteins	  generates	  amino	  acids	  thus	  activate	  mTORC1	  
activity	  (Figure	  6).	  Rheb1	  function	  and	  association	  with	  membrane	  is	  most	  likely	  
through	  the	  CAAX	  domain,	  which	  allows	  for	  farnesylation	  modifications.	  Myc-­‐Rheb1	  
(S16H)	  associates	  with	  membranes	  and	  a	  large	  yet	  specific	  set	  of	  proteins	  by	  
immunofluroescence,	  immunoblotting	  and	  LC/MS/MS	  analysis.	  The	  specificity	  of	  
the	  protein	  associations	  are	  demonstrated	  by	  the	  fact	  that	  many	  proteins	  are	  found	  
in	  the	  same	  LP2	  sub-­‐cellular	  fractions	  as	  Rheb1,	  however	  only	  very	  specific	  
interactors	  were	  identified.	  We	  found	  myc-­‐Rheb1	  (S16H)	  associates	  with	  and	  
transport	  receptors	  such	  as	  GluR2	  most	  likely	  after	  receptor	  endocytosis	  driven	  by	  
synaptic	  activity,	  but	  not	  GluR1.	  We	  also	  found	  myc-­‐Rheb1	  (S16H)	  associate	  with	  
ubiquitinylated	  proteins	  such	  as	  Shank3	  and	  ubiquitinylation	  regulating	  proteins.	  
These	  associations	  suggest	  myc-­‐Rheb1	  (S16H)	  may	  traffic	  proteins	  to	  either	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lysosomes	  or	  proteosomes	  for	  degradation.	  Subsequent	  to	  the	  protein	  degradation	  
process	  by	  the	  lysosome	  and	  or	  proteosomes,	  amino	  acids	  are	  generated	  which	  
promotes	  mTORC1	  translation	  to	  the	  lysosomal	  surfaces	  for	  activation	  via	  Rag	  
protein	  complex	  (Bar-­‐Peled	  and	  Sabatini).	  	  It	  is	  noteworthy	  that	  we	  found	  myc-­‐
Rheb1	  (S16H)	  to	  specifically	  associate	  with	  a	  set	  of	  proteins	  from	  the	  LP2	  fraction	  
but	  not	  all	  of	  the	  proteins	  that	  were	  found	  in	  the	  LP2	  fraction.	  This	  indicates	  that	  the	  
associations	  are	  rather	  selective	  and	  not	  due	  to	  enrichment	  of	  the	  overall	  proteins	  in	  
the	  LP2	  fraction.	  Our	  finding	  that	  Rheb1	  and	  mTOR	  are	  enriched	  in	  synaptic	  vesicle-­‐
enriched	  fractions	  by	  biochemical	  experiments	  supports	  this	  notion.	  Moreover,	  p-­‐
mTOR	  signal	  by	  Western	  blot	  analysis	  showed	  enrichment	  in	  the	  LP2	  fraction	  
indicating	  active	  mTOR	  is	  localized	  in	  the	  same	  fraction	  as	  Rheb1.	  In	  support	  that	  
mTOR	  activity	  is	  dependent	  on	  amino	  acids	  availability,	  we	  found	  that	  inhibition	  of	  
proteosomes	  with	  MG132	  or	  amino	  acids	  withdraw	  reduces	  mTORC1	  activity	  
significantly.	  Addition	  of	  amino	  acids	  alone	  was	  able	  to	  rescue	  the	  mTORC1	  activity	  
in	  cells	  adapted	  to	  nutrient	  and	  amino	  acids	  free	  media.	  	  
Amyloid	  Precursor	  Protein	  (APP)	  is	  a	  synaptic	  transmembrane	  protein	  that	  is	  
subjected	  proteo-­‐cleavage	  events	  by	  Bace1	  through	  endocytosis	  (Cole,	  Stock	  et	  al.).	  
Previous	  studies	  showed	  that	  APP	  processing	  is	  activity	  dependent	  and	  regulated	  by	  
Arc	  through	  the	  endosomal	  pathway	  (Wu,	  Petralia	  et	  al.).	  We	  found	  myc-­‐Rheb1	  
(S16H)	  association	  with	  Arc,	  Amyloid	  Precursor	  Protein	  (APP)	  and	  fragments	  of	  
processed	  APP	  by	  Western	  blot	  analysis	  in	  co-­‐IP	  experiments.	  These	  association	  are	  
intriguing	  as	  it	  suggest	  that	  myc-­‐Rheb1	  associates	  with	  endosomes	  that	  are	  involved	  
in	  APP	  processing	  that	  is	  dependent	  on	  Arc.	  Base	  on	  previous	  studies	  that	  in	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Alzheimer’s	  Disease	  (AD)	  mTOR	  signaling	  is	  elevated,	  it	  would	  suggest	  that	  increase	  
in	  APP	  processing	  due	  to	  mutations	  may	  drive	  endosome	  trafficking	  and	  elevate	  
mTOR	  signaling	  through	  Rheb1	  (Ma,	  Hoeffer	  et	  al.).	  Our	  findings	  provide	  addition	  
protein	  and	  mechanistic	  therapeutic	  targets	  in	  AD	  treatment.	  
Curiously,	  we	  found	  interaction	  of	  Rheb1	  with	  mGluR5	  in	  a	  membrane	  
dependent	  fashion	  as	  the	  association	  was	  preserved	  only	  with	  1%	  Triton-­‐X	  100	  
treatment.	  We	  demonstrated	  that	  inhibition	  of	  group	  1	  metabotropic	  receptors	  
results	  in	  reduction	  of	  mTORC1	  activity.	  These	  results	  suggest	  a	  tight	  linkage	  
between	  group	  1	  metabotropic	  receptors	  and	  mTOR	  activity.	  However,	  it	  is	  not	  
understood	  as	  to	  the	  signal	  transduction	  mechanism	  of	  mGluRs	  to	  mTOR.	  Previous	  
investigations	  have	  shown	  that	  stimulation	  of	  mGluR5	  have	  positive	  impact	  on	  
mTORC1	  activity	  (Ronesi	  and	  Huber	  2008).	  It	  will	  be	  important	  to	  determine	  
whether	  mGluR	  signaling	  is	  couple	  on	  the	  plasma	  membrane	  or	  requires	  endocytic	  
mechanisms.	  Investigations	  that	  demonstrate	  elegant	  TRKB	  and	  MAP-­‐kinase	  
signaling	  mechanism	  is	  dependent	  on	  endocytic	  machineries	  have	  previously	  been	  
demonstrated	  (Harrington,	  St	  Hillaire	  et	  al.).	  Examinations	  to	  decipher	  if	  agonist	  
induced	  activation	  of	  mGluR5	  causes	  endocytosis	  of	  the	  receptor	  and	  association	  
with	  Rheb1	  to	  form	  a	  signalosome-­‐like	  entity	  is	  warranted	  as	  the	  implications	  for	  
underlying	  mGluR	  and	  mTOR	  signaling	  mechanisms	  are	  tremendous	  in	  learning	  and	  
memory	  (Osterweil,	  Krueger	  et	  al.).	  
Together	  these	  findings	  suggest	  that	  basal	  synaptic	  activity	  driven	  protein	  
turnover	  provides	  a	  baseline	  for	  mTORC1	  activity	  level	  in	  the	  distal	  dendrite	  or	  at	  
the	  synapse	  of	  neurons	  via	  turnover	  of	  synaptic	  proteins.	  Thus	  mTOR	  activity	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responds	  in	  a	  synaptic	  activity-­‐dependent	  manner.	  	  Subsequent	  intra-­‐	  or	  extra-­‐	  
cellular	  may	  changes	  alter	  the	  mTOR	  pathway	  and	  impact	  mTORC1	  integration	  
function	  and	  outputs.	  Aberrant	  drives	  of	  the	  endocytic	  pathway	  due	  to	  enhanced	  
protein	  turnover	  by	  ubiquitinylation	  or	  APP	  processing	  due	  to	  mutations	  would	  lead	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
	  































































































Calcium	  signals	  are	  fundamental	  to	  numerous	  types	  of	  synaptic	  plasticity	  
events	  including	  LTP	  and	  LTD	  (Yasuda).	  In	  pilot	  studies	  described	  here,	  we	  found	  
that	  elevation	  of	  intracellular	  Ca2+	  can	  activate	  mTORC1.	  Biochemical	  studies	  that	  
assay	  phosphorylation	  of	  Akt	  and	  TSC	  suggest	  that	  Ca2+	  activates	  mTORC1	  by	  a	  
mechanism	  that	  is	  distinct	  from	  canonical	  growth	  factor	  or	  receptor-­‐activated	  
mTORC1.	  This	  “non-­‐canonical”	  mechanism	  may	  be	  important	  in	  diseases	  such	  as	  
Alzheimer’s	  disease,	  as	  a	  mechanism	  for	  persistent	  activation	  of	  mTORC1.	  My	  
studies	  further	  suggest	  a	  role	  Ca2+	  influx	  through	  Orai	  channels	  gated	  by	  STIM1	  as	  a	  
mechanism	  for	  Ca2+	  influx-­‐dependent	  activation	  of	  mTORC1,	  and	  provide	  one	  of	  the	  






We	  crossed	  CamKII-­‐Cre	  with	  floxed	  Rheb1	  mice	  to	  generate	  CamKII-­‐Cre	  
mediated	  Rheb1	  knockout	  mice	  (Rheb1-­‐KO).	  Rheb1-­‐KOs	  also	  did	  not	  display	  any	  
gross	  anatomical	  or	  phenotypical	  abnormalities.	  The	  excision	  of	  Rheb1	  and	  
alterations	  of	  the	  mTOR	  signaling	  pathway	  were	  examined	  by	  Western	  blot	  analysis	  
of	  forebrain	  lysates	  derived	  from	  Rheb1-­‐KOs	  and	  littermate	  controls	  (Figure	  2).	  
Rheb1-­‐KOs	  showed	  a	  selective	  deficit	  for	  mTORC1	  signaling	  as	  demonstrated	  by	  
reduced	  phosphorylation	  of	  s6.	  The	  reduction	  of	  S6	  kinase	  activity	  reduces	  the	  
negative	  feed	  back	  loop	  on	  mTORC2,	  thus	  leading	  to	  an	  increase	  in	  phosphorylation	  
of	  Akt	  S473	  and	  TSC2.	  In	  order	  to	  dissect	  the	  pathways	  that	  affect	  mTOR	  signaling	  
we	  utilized	  the	  cortical	  neuron	  culture	  system	  derived	  from	  homozygous,	  
heterozygous	  Rheb1-­‐KOs	  and	  control	  mice.	  Cultured	  neurons	  derived	  from	  Rheb1-­‐
KOs	  showed	  a	  loss	  of	  mTOR-­‐mediated	  phosphorylation	  of	  s6	  (Figure	  3).	  VDCC	  
activation	  has	  been	  demonstrated	  to	  play	  crucial	  role	  in	  various	  forms	  of	  LTP	  (Kato,	  
Kassai	  et	  al.).	  Treatment	  with	  a	  VDCC	  agonist,	  BayK	  S-­‐,	  led	  to	  an	  increase	  in	  
intracellular	  calcium	  concentration	  and	  enhanced	  mTORC1	  activity	  in	  the	  floxed	  
(F/F)	  and	  heterozygous	  KO	  (Het)	  in	  the	  neurons	  but	  not	  in	  the	  Rheb1-­‐KO	  neurons.	  
Furthermore,	  treatment	  with	  Rapamycin	  in	  combination	  with	  BayK	  S-­‐	  diminished	  
the	  phosphorylation	  of	  s6	  demonstrating	  that	  the	  phosphorylation	  of	  s6	  is	  
dependent	  on	  mTOR	  signaling.	  mTORC1	  activation	  in	  this	  set	  of	  experiments	  
showed	  that	  basal	  and	  stimulated	  mTORC1	  activity	  responds	  in	  a	  Rheb1	  dose	  
dependent	  manner.	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We	  examined	  further	  the	  observation	  that	  VDCC	  stimulation	  can	  activate	  
mTORC1	  signaling	  (Figure	  4).	  In	  WT	  neuronal	  cultures,	  application	  of	  BayK	  S-­‐	  did	  
not	  lead	  to	  any	  significant	  changes	  in	  the	  kinase	  cascade	  of	  the	  known	  upstream	  
activators	  of	  mTORC1	  such	  as	  Akt	  and	  TSC2.	  As	  expected,	  addition	  of	  10-­‐DEBC,	  a	  
specific	  pharmacological	  inhibitor	  of	  Akt,	  resulted	  in	  a	  reduction	  of	  s6	  
phosphorylation.	  However,	  this	  reduction	  was	  reverted	  upon	  application	  of	  BayK	  S-­‐.	  
Immunoblotting	  of	  known	  upstream	  activators	  of	  mTORC1	  demonstrated	  that	  
inhibition	  of	  Akt	  lead	  to	  a	  subsequent	  disruption	  of	  phosphorylation	  in	  Akt,	  TSC2,	  
and	  mTOR	  suggesting	  that	  calcium	  activation	  of	  mTORC1	  is	  not	  through	  the	  
canonical	  pathway.	  The	  decrease	  in	  mTORC1	  activity	  by	  10-­‐DEBC	  applications	  in	  the	  
cultures	  also	  resulted	  in	  an	  increase	  in	  eEF2	  phosphorylation	  (T56).	  P-­‐eEF2	  is	  
dependent	  on	  eEF2	  kinase,	  which	  is	  inhibited	  by	  mTOR	  to	  facilitate	  elongation	  in	  the	  
protein	  translation	  step.	  The	  combination	  treatment	  of	  10-­‐DEBC	  and	  BayK	  S-­‐	  led	  to	  
a	  slight	  increase	  in	  the	  phosphorylation	  of	  mTOR	  (S2448)	  suggesting	  that	  mTOR	  is	  
activated.	  Concurrent	  with	  the	  rescue	  of	  P-­‐s6,	  eEF2	  phosphorylation	  was	  also	  
slightly	  reduced,	  suggesting	  a	  rescue	  of	  mTORC1	  function.	  Rheb1	  levels	  were	  
examined	  to	  confirm	  that	  the	  change	  in	  mTORC1	  activity	  was	  due	  to	  signal	  
transduction	  cascade	  rather	  than	  variation	  in	  Rheb-­‐1	  protein	  levels.	  	  
Next,	  we	  examined	  whether	  mTORC1	  signaling	  would	  be	  affected	  by	  the	  
inhibition	  of	  Ca2+	  influx.	  SKF	  96365	  was	  utilized	  to	  inhibit	  wide	  range	  of	  Ca2+	  
channels	  including	  TRPC	  family	  and	  Orai	  channels	  (Figure	  5).	  P-­‐s6	  was	  drastically	  
reduced	  upon	  treatment	  with	  SKF	  96365,	  at	  the	  same	  time	  that	  P-­‐eEF2	  increased.	  
There	  were	  no	  apparent	  changes	  in	  the	  canonical	  mTOR	  signaling	  pathway	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suggested	  by	  the	  preserved	  level	  of	  P-­‐Akt.	  Other	  Ca2+	  channel	  inhibitors	  such	  as	  a	  
stereoisomer	  of	  BayK	  S-­‐	  also	  blocked	  signaling	  mediated	  by	  mTORC1	  (data	  not	  
shown).	  	  
In	  combination	  with	  pharmacological	  manipulations,	  we	  utilized	  biochemical	  
and	  molecular	  approaches	  to	  examine	  Ca2+	  and	  activation	  of	  mTORC1.	  Previous	  
investigations	  have	  characterized	  the	  mechanisms	  of	  calcium	  store	  activation	  and	  
refilling	  (Soboloff,	  Rothberg	  et	  al.).	  Orai	  activating	  fragment	  of	  STIM1,	  termed	  Stim-­‐
Orai-­‐Activation-­‐Region	  (SOAR),	  can	  trigger	  calcium	  influx	  from	  extracellular	  space	  
through	  the	  plasma	  membrane	  (Yuan,	  Zeng	  et	  al.).	  Orai	  mRNA	  is	  expressed	  in	  brain.	  
Expression	  via	  Sinbis	  virus	  encoding	  GFP-­‐tagged	  SOAR	  in	  dissociated	  neuron	  
cultures	  resulted	  in	  robust	  increase	  in	  mTORC1	  activity	  (Figure	  6).	  	  At	  the	  time	  I	  did	  
these	  experiments,	  SOAR	  was	  thought	  to	  be	  entirely	  specific	  for	  Orai	  channels.	  
However,	  recent	  studies	  suggest	  SOAR	  may	  also	  activate	  VSCC.	  Accordingly,	  these	  
studies	  will	  need	  to	  be	  extended	  by	  additional	  approaches	  to	  directly	  implicate	  Orai.	  
For	  example,	  we	  could	  check	  that	  this	  effect	  is	  not	  blocked	  by	  VSCC	  antagonists,	  or	  
that	  effects	  of	  SOAR	  are	  absent	  in	  Orai1/2/3	  KO	  neurons.	  	  	  
The	  lack	  of	  a	  calcium	  responsive	  participant	  in	  the	  well-­‐studied	  canonical	  
mTORC1	  activating	  pathway	  lead	  me	  to	  a	  pharmacological	  screen	  of	  calcium	  
sensitive	  proteins	  that	  may	  modulate	  mTORC1	  activity.	  Cortical	  neurons	  were	  
treated	  with	  10-­‐DEBC,	  W7,	  a	  relatively	  selective	  Ca2+/Calmodulin	  inhibitor,	  or	  the	  
combination	  of	  both	  (Figure	  7).	  W7	  treatment	  of	  neuron	  culture	  eliminated	  pS6.	  
Inhibition	  of	  Akt	  with	  10-­‐DEBC	  also	  reduced	  pS6.	  BayK	  S-­‐	  in	  the	  presence	  of	  W7	  did	  
not	  rescue	  the	  loss	  of	  mTORC1.	  This	  contrasts	  with	  the	  previous	  experiment	  where	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BayK	  S-­‐	  was	  able	  to	  rescue	  the	  inhibitory	  effect	  of	  10-­‐DEBC,	  and	  suggests	  that	  
Ca2+/Calmodulin	  may	  be	  a	  calcium	  responsive	  modulator	  of	  mTORC1	  that	  is	  not	  
dependent	  on	  Akt.	  Published	  studies	  have	  shown	  that	  activation	  of	  Mitogen	  
Activated	  Protein	  Kinase	  (MapK)	  pathway	  may	  lead	  to	  phosphorylation	  of	  s6	  via	  the	  
activation	  of	  TSC2	  or	  s6	  kinase	  (Ronesi	  and	  Huber).	  I	  used	  U1026,	  a	  specific	  MapK	  
inhibitor,	  to	  exclude	  this	  possible	  mechanism	  as	  a	  mediator	  of	  the	  Ca2+	  activation	  of	  
mTORC1.	  In	  the	  presence	  of	  U1026,	  phosphorylation	  of	  Erk	  was	  abolished,	  however,	  
Ca2+	  flux	  by	  the	  addition	  of	  BayK	  S-­‐	  compound	  was	  still	  able	  to	  activate	  mTORC1	  
(Data	  not	  shown).	  	  
Having	  implicated	  a	  non-­‐canonical	  pathway	  that	  can	  bypass	  the	  canonical	  
pathway	  to	  activate	  mTORC1,	  we	  examined	  if	  the	  vice	  versa	  regulation	  would	  be	  
possible.	  In	  cortical	  neurons	  treated	  with	  insulin,	  and	  BayK	  S-­‐	  was	  able	  to	  increase	  
mTORC1	  activity.	  	  Inhibition	  of	  Ca2+/Calmodulin	  with	  W7	  abolished	  mTORC1	  
activity	  and	  BayK	  S-­‐	  was	  not	  able	  to	  rescue	  mTORC1	  activity	  in	  the	  presence	  of	  W7	  
(Figure	  8).	  	  However,	  the	  addition	  of	  insulin	  rescued	  mTORC1	  activity	  in	  the	  
presence	  of	  W7.	  This	  suggests	  that	  W7	  does	  not	  block	  canonical	  signaling	  to	  activate	  
mTORC1.	  
	   Based	  on	  the	  preceding	  findings,	  I	  hypothesized	  that	  non-­‐canonical	  activation	  
of	  mTORC1	  might	  occur	  when	  pS6	  increases	  in	  the	  absence	  of	  increases	  of	  AKT308	  
phosphorylation.	  	  I	  then	  examined	  mice	  that	  were	  engaged	  in	  a	  learning	  protocol	  
that	  could	  invoke	  LTP-­‐like	  plasticity	  in	  hippocampus.	  4	  weeks	  old	  mice	  were	  
individually	  caged	  and	  desensitized	  for	  7	  days.	  On	  day	  7,	  brains	  from	  Control	  and	  
Rheb1-­‐KO	  mice	  were	  isolated	  from	  either	  cage	  controls	  or	  after	  being	  subjected	  to	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activity	  chamber	  for	  10	  min.	  The	  brain	  was	  dissected	  sagittally	  into	  halves.	  
Immunostaining	  showed	  increase	  p-­‐s6	  levels	  in	  the	  Dentate	  Gyrus,	  CA3	  and	  CA1	  
region	  in	  the	  animals	  that	  engaged	  in	  exploration	  compared	  to	  caged	  controls.	  
Immunoblotting	  confirmed	  an	  increase	  in	  pS6.	  However,	  with	  phospho	  specific	  
antibodies	  against	  the	  canonical	  pathway	  did	  not	  show	  increased	  phosphorylation	  
of	  PDK1,	  Akt,	  or	  TSC2	  (Figure	  9).	  Western	  blot	  analysis	  also	  indicated	  that	  the	  
signaling	  by	  MapK	  pathway	  in	  the	  explored	  group	  was	  not	  significantly	  more	  than	  
the	  control	  caged	  group	  (data	  not	  shown).	  This	  preliminary	  result	  suggests	  that	  the	  
activation	  of	  mTORC1	  in	  the	  in-­‐vivo	  exploration	  paradigm	  is	  due	  to	  the	  activation	  of	  
a	  non-­‐canonical	  pathway.	  	  
Ca2+	  signaling	  is	  reportedly	  disrupted	  in	  neurons	  that	  express	  
APPswe/PS1∆e9	  transgene.	  We	  examined	  dissociated	  cortical	  neuron	  cultures	  
derived	  from	  WT	  and	  APPSwe/PS1	  on	  DIV-­‐14	  for	  basal	  mTORC1	  activity	  and	  insulin	  
response.	  Western	  analysis	  showed	  an	  increase	  of	  p-­‐s6	  in	  neurons	  derived	  from	  
APPSwe/PS1	  at	  the	  basal	  level	  upon	  comparison	  with	  control	  neurons	  (Figure	  10).	  In	  
contrast	  to	  control	  neurons,	  APPSwe/PS1	  neurons	  were	  no	  longer	  sensitive	  to	  Insulin	  
stimulation.	  Immunoblotting	  of	  p-­‐IRS	  showed	  a	  slight	  increase	  of	  signal	  in	  
APPSwe/PS1	  neurons,	  suggesting	  that	  elevated	  mTORC1	  activity	  feeds	  to	  IRS	  to	  
inhibit	  insulin	  stimulations.	  To	  examine	  the	  feedback	  inhibition	  in	  more	  detail,	  we	  
looked	  at	  Phosphoinositol	  dependent	  kinase	  1	  (PDK1),	  a	  kinase	  responsive	  to	  PI3K	  
activation.	  Insulin	  receptor	  activation	  causes	  dimerization	  of	  its	  subunits	  clustering	  
insulin	  receptor	  substrate	  leading	  to	  phosphorylation	  and	  activation	  of	  PI3K.	  
Subsequently,	  PI3K	  phosphorylates	  PIP2	  and	  produces	  PIP3	  that	  triggers	  the	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activation	  of	  PDK1.	  PDK1	  in	  APPSwe/PS1	  neurons	  was	  not	  activated	  with	  the	  
treatment	  of	  insulin	  in	  contrast	  to	  the	  control	  neurons.	  	  
	  
Discussion	  
The	  presented	  studies	  suggest	  the	  existence	  of	  a	  non-­‐canonical	  mTOR	  
activation	  pathway	  via	  calcium	  signals,	  which	  is	  also	  Ca2+/Camodulin	  dependent.	  
These	  observations	  offer	  an	  interesting	  alternative	  to	  the	  canonical	  mTOR	  activation	  
cascade,	  which	  does	  not	  include	  any	  calcium	  responsive	  participants.	  The	  non-­‐
canonical	  mTOR	  activation	  pathway	  via	  calcium	  signals	  are	  particularly	  intriguing	  in	  
cell	  types	  that	  harbor	  extensive	  numbers	  of	  calcium	  channels	  and	  are	  extremely	  
sensitive	  to	  varying	  calcium	  concentrations	  such	  as	  lymphocytes,	  cardio-­‐myocytes	  
and	  neurons.	  Dynamic	  calcium	  fluxes	  in	  these	  cell	  types	  mediate	  cellular	  functions	  
such	  as	  contractions,	  differentiations,	  and	  modifications	  of	  synaptic	  efficiency	  (Efe,	  
Hilcove	  et	  al.)	  (Oh-­‐Hora,	  Yamashita	  et	  al.)	  (Zamponi	  and	  Currie).	  In	  neuron	  culture	  
preparations	  we	  used	  pharmacological	  modulators	  of	  calcium	  channels	  and	  
molecular	  expression	  constructs	  modulating	  CRAC	  and	  STIM1	  to	  demonstrate	  a	  
direct	  correlation	  of	  mTOR	  activity	  with	  calcium	  availability.	  Increasing	  calcium	  
influx	  with	  stimulation	  of	  VDCC	  or	  expression	  of	  SOAR	  increased	  mTORC1	  activity	  
while	  inhibition	  of	  VDCC,	  TRPC	  or	  expression	  of	  dominant	  negative	  SOAR	  and	  ORAI	  
reduced	  mTORC1	  activity	  in	  our	  studies.	  Moreover,	  through	  a	  pharmacological	  
screen,	  we	  identified	  Ca2+/Calmodulin	  has	  a	  candidate	  mediator	  of	  the	  non-­‐
canonical	  mTORC1	  signaling	  using	  W7	  compound.	  Characterization	  of	  the	  molecular	  
pathway	  mediating	  the	  calcium	  response	  in	  the	  mTOR	  pathway	  revealed	  that	  the	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canonical	  pathway	  was	  not	  involved.	  Using	  10-­‐DEBC,	  we	  demonstrated	  that	  calcium	  
activation	  of	  mTORC1	  pathway	  did	  not	  require	  the	  canonical	  activation	  of	  Akt.	  In	  
addition,	  we	  were	  able	  to	  activate	  mTORC1	  signaling	  by	  stimulation	  with	  Insulin	  in	  
the	  presence	  of	  W7.	  These	  results	  suggest	  the	  existence	  of	  separately	  regulated	  
canonical	  and	  non-­‐canonical	  mTORC1	  signaling	  pathway	  (Figure	  11).	  Furthermore,	  
using	  in	  vivo	  exploration	  activity	  experiments	  that	  activate	  L-­‐type	  VDCC	  in	  
hippocampus,	  findings	  suggest	  that	  a	  non-­‐canonical	  mTORC1	  signaling	  pathway	  
mediates	  the	  increase	  in	  mTORC1	  signaling.	  	  
	   Alzheimer’s	   Disease	   (AD)	   has	   been	   highly	   associated	   with	   impairment	   of	  
cognitive	  function,	  which	  reduces	  to	  interrupted	  function	  at	  the	  neuronal	  synapses	  
(Selkoe).	   As	   compelling	   mouse	   models,	   which	   over-­‐express	   the	   APPSwe	   human	  
transgene	   in	   the	   background	   with	   a	   Presenilin-­‐1	   ∇e9	   mutation	   have	   been	   well	  
established,	  it	  provides	  a	  platform	  for	  careful	  dissection	  of	  the	  contributing	  factors	  
to	   the	   disease.	   Correlation	   between	   disruptions	   in	   Ca2+	   homeostasis	   and	   AD	   has	  
been	  well	   established	   after	   the	   initial	   presentation	   of	   the	   “Calcium	  hypothesis	   for	  
Alzheimer’s	   Disease	   and	   brain	   aging”	   by	   Zaven	   Khachaturian	   in	   1989	   (LaFerla).	  
Evidences	  of	  human	  and	  mice	  models	  demonstrating	  alterations	  in	  calcium	  signaling	  
during	  the	  initial	  phase	  of	  the	  disease	  before	  development	  of	  symptoms	  have	  been	  
provided.	   Furthermore,	   careful	   studies	   have	   demonstrated	   that	   APP/Swe/PS1	  
transgenic	   mice	   with	   cortical	   plaques	   have	   disrupted	   spine-­‐dendritic	   calcium	  
compartmentalization	   and	   regulations,	   which	   are	   highly	   regulated	   in-­vivo	  
(Kuchibhotla,	  Goldman	  et	   al.).	   The	   increase	   in	   intracellular	  Ca2+	   levels,	   [Ca2+]I,	   has	  
been	  correlated	  with	  Aβ	  generated	  from	  APP	  by	  the	  γ-­‐Secretace,	  Bace1,	  by	  forming	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Ca2+	  permeable	  pores	  at	  the	  plasma	  membrane.	  Another	  possible	  contributing	  factor	  
to	   the	   rise	   in	   [Ca2+]i	   is	   the	   PS1	  ∇e9	  mutation,	  which	   enhances	   IP3R	   induced	   Ca2+	  
release	   from	   the	  ER	   (LaFerla).	   Recent	   studies	   have	   linked	  hyper	  mTORC1	   activity	  
with	   AD	   by	   the	   observation	   that	   mTOR	   and	   its	   target	   eIF4-­‐EBP	   were	   highly	  
phosphorylated	   (Li,	   Alafuzoff	   et	   al.).	   In	   a	   separate	   study,	   the	   over-­‐active	  mTORC1	  
signaling	  can	  be	   further	   correlated	  with	   the	  observation	   that	  APP	   transgenic	  mice	  
have	  an	  increase	  in	  cortical	  neuron	  size	  implicative	  of	  the	  establish	  role	  of	  mTORC1	  
function	  in	  cell	  size	  growth	  (Ohne,	  Takahara	  et	  al.).	  Furthermore,	  mTORC1	  has	  been	  
shown	  to	  facilitate	  the	  translation	  of	  Tau,	  a	  protein	  when	  hyper-­‐phosphorylated	  is	  a	  
hallmark	  AD	  pathology.	  (Liu,	  Zhou	  et	  al.).	  The	  facilitated	  translation	   is	   through	  the	  
signature	  5’TOP	  sequence	  motif	  found	  in	  5’	  UTR	  region	  of	  the	  mRNA,	  which	  highly	  
regulated	  and	  specific	  to	  the	  function	  of	  mTORC1.	  Interestingly,	  insulin	  resistance	  as	  
well	   as	   increased	   phosphorylation	   of	   the	   Insulin	   Receptor	   Substrate-­‐1	   (IRS-­‐1)	  
indicative	   of	   inactivation	   by	  mTORC1	   has	   been	   observed	   (Moloney,	   Griffin	   et	   al.).	  
Insulin	   induced	   signaling	   of	   Akt/mTORC1	   can	   also	   be	   described	   as	   the	   canonical	  
mTORC1	  signaling	  pathway.	  The	  paradoxical	  observation	  that	  mTORC1	  signaling	  is	  
elevated	  while	   IRS-­‐1	   is	   inactive	   presents	   an	   interesting	   platform	   for	   studying	   the	  
relative	   contributions	   of	   the	   canonical	   and	   non-­‐canonical	   pathway	   in	   mTORC1	  
signaling.	   Combining	   the	   loss	   of	   homeostasis	   regulation	   of	   Ca2+	   and	   rise	   of	   [Ca2+]i	  
with	  the	  observation	  that	  mTORC1	  is	  overactive,	  the	  working	  model	  is	  such	  that	  the	  
non-­‐canonical	   pathway	   is	   over	   represented	   in	   AD	   thus	   feeding	   back	   to	   IRS-­‐1	   and	  
inhibiting	  the	  canonical	  pathway.	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Utilizing	  cultured	  neurons	  derived	  from	  mouse	  models	  of	  AD	  we	  found	  
increased	  mTORC1	  activity	  in	  comparison	  with	  control	  neurons.	  Moreover,	  cultured	  
neurons	  from	  AD	  mouse	  models	  were	  not	  sensitive	  to	  Insulin	  stimulation.	  These	  
findings	  suggest	  that	  the	  increase	  in	  basal	  mTORC1	  activity	  due	  to	  the	  activation	  of	  
non-­‐canonical	  pathway	  is	  capable	  of	  eliciting	  the	  well-­‐characterized	  feedback	  
inhibition	  to	  the	  insulin	  receptor,	  thus	  blunting	  normal	  response	  to	  extracellular	  
stimuli.	  The	  lack	  of	  response	  to	  insulin	  stimulation	  in	  AD	  brains	  have	  been	  studied,	  
discussed	  and	  often	  termed	  as	  “Type	  III	  diabetes”	  by	  other	  researchers	  (de	  la	  
Monte).	  Future	  experiments	  to	  dissect	  the	  non-­‐canonical	  pathway	  will	  be	  necessary	  
to	  gain	  further	  understanding	  of	  the	  role	  that	  it	  plays	  in	  AD	  pathology.	  	  
A	  published	  study	  suggests	  that	  amino	  acids	  activate	  mTORC1	  via	  
Ca2+/Calmodulin	  signaling	  to	  a	  PI3K	  class	  III	  member,	  VPS-­‐34	  (Gulati,	  Gaspers	  et	  al.).	  
Upon	  the	  characterization	  of	  VPS-­‐34	  in	  the	  non-­‐canonical	  pathway,	  it	  may	  present	  
as	  a	  valuable	  target	  to	  specifically	  disrupt	  the	  non-­‐canonical	  pathway	  in	  the	  AD	  
model.	  shRNA	  mediated	  knock	  down	  of	  VPS-­‐34	  would	  be	  utilized	  to	  inhibit	  the	  non-­‐
canonical	  pathway	  in	  attempt	  to	  restore	  the	  sensitivity	  of	  the	  canonical	  pathway.	  
	   The	  presented	  data	  suggest	  that	  Transient	  Receptor	  Potential	  Cat-­‐ion	  
Channel	  (TRPC),	  VDCC,	  and	  stores	  from	  the	  endoplasmic	  reticulum	  (ER)	  can	  provide	  
a	  source	  of	  calcium	  to	  modulate	  mTORC1.	  It	  would	  be	  an	  objective	  to	  resolve	  the	  
course	  that	  calcium	  takes	  from	  these	  channels	  and	  stores.	  One	  possibility	  is	  that	  the	  
calcium	  enters	  through	  the	  calcium	  channels	  and	  raises	  intracellular	  calcium	  
concentrations	  directly.	  Another	  potential	  mechanism	  would	  be	  that	  calcium	  enters	  
through	  channels	  and	  fills	  the	  calcium	  store	  in	  the	  ER	  then	  subsequently	  raises	  the	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intracellular	  levels.	  The	  two	  contrasting	  paths	  of	  Ca2+	  flux	  may	  be	  differentiated	  with	  
the	  recent	  identification	  of	  Ca2+	  release-­‐activating	  Ca2+	  channel	  (CRAC)	  Orai,	  and	  
Stromal	  Interaction	  molecule	  (STIM).	  STIM	  is	  the	  transmembrane	  Ca2+	  sensor	  
located	  on	  the	  ER	  that	  activates	  Orai	  upon	  store	  depletion	  for	  refilling	  store	  calcium.	  
Such	  an	  investigation	  allows	  for	  the	  understanding	  of	  the	  role	  that	  calcium,	  as	  a	  
second	  messenger,	  dynamically	  regulate	  protein	  translation	  to	  facilitate	  plasticity	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STIM1	  regulates	  hippocampal	  NMDA-­LTD	  through	  Calcinuerin	  	  
	  
Introduction	  
My	  preliminary	  studies	  in	  Chapter	  5	  suggested	  that	  Ca2+	  entry	  through	  Orai	  or	  
other	  store-­‐dependent	  ion	  channels	  may	  be	  important	  in	  activation	  of	  mTORC1,	  and	  
other	  aspects	  of	  synaptic	  physiology.	  	  Recent	  advances	  in	  understanding	  the	  
molecular	  basis	  of	  Ca2+	  entry	  into	  cells	  via	  non-­‐voltage	  sensitive	  channels	  lead	  me	  
to	  focus	  on	  these	  pathways	  and	  their	  role	  in	  synaptic	  plasticity.	  	  
Calcium	  mobilization	  underlies	  essential	  processes	  to	  achieve	  different	  forms	  of	  
plasticity	  in	  a	  neuron.	  In	  addition	  to	  calcium	  import	  from	  extra-­‐cellular	  space,	  ER	  
store	  calcium	  releases	  into	  the	  cytosol	  also	  have	  a	  significant	  role	  in	  many	  forms	  of	  
synaptic	  plasticity	  (Woods	  and	  Padmanabhan)	  (Bogeski,	  Kilch	  et	  al.).	  Recent	  
research	  has	  demonstrated	  that	  the	  induction	  of	  LTP	  and	  LTD	  can	  be	  blocked	  by	  
prior	  depletion	  of	  ER	  calcium	  with	  compounds	  such	  as	  thapsigargin	  (Wang,	  Rowan	  
et	  al.).	  Furthermore,	  studies	  have	  shown	  that	  mice	  that	  lack	  Ryanodine	  receptor	  
(RyR3)	  have	  impaired	  LTD,	  while	  mice	  that	  lack	  type	  1	  Inositol	  Phosphate	  (IP3)	  
receptors	  have	  enhanced	  LTP.	  It	  has	  also	  been	  suggested	  that	  the	  dynamic	  function	  
and	  modulation	  of	  store	  Ca2+	  may	  be	  the	  underlying	  mechanism	  differentiating	  
homo-­‐	  vs.	  heterosynaptic	  plasticity	  (Fitzjohn	  and	  Collingridge).	  The	  long	  sought	  
after	  molecules	  that	  contribute	  mediate	  the	  Ca2+	  during	  Store-­‐Operated	  Ca2+	  Entry	  
(SOCE)	  was	  identified	  through	  an	  RNAi	  screen	  reported	  in	  2006.	  Stromal	  Interacting	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Molecule	  1	  and	  2	  (STIM1,	  STIM2)	  are	  type-­‐I	  membrane	  protein	  and	  detects	  store	  
calcium	  by	  its	  EF-­‐Hand	  domain	  located	  in	  the	  lumen	  of	  the	  ER.	  The	  EF	  hand	  domain	  
of	  STIM1	  has	  a	  K1/2	  of	  approximately	  200-­‐600µM	  for	  Ca2+	  while	  STIM2	  has	  a	  higher	  
sensitivity	  to	  Ca2+	  changes	  with	  a	  K1/2	  of	  approximately	  400µM.	  The	  difference	  in	  the	  
binding	  kinetics	  is	  suggestive	  that	  STIM2	  controls	  the	  basal	  cytoplasmic	  and	  ER	  Ca2+	  
levels.	  Store	  depletion	  of	  Ca2+	  causes	  rapid	  oligomerization	  of	  STIM1	  and	  migration	  
of	  the	  cluster	  associated	  with	  the	  ER	  membrane	  to	  the	  plasma	  membrane	  where	  
STIM1	  binds	  and	  activates	  the	  Store-­‐Operated	  Ca2+	  Entry	  (SOCE)	  channel	  
component,	  Orai	  (Model)	  (Clapham).	  Studies	  have	  shown	  that	  the	  active	  pore	  is	  
composed	  of	  four	  Orai	  molecules	  while	  during	  the	  resting	  state,	  Orai	  proteins	  are	  
found	  as	  dimers.	  Three	  Orai	  proteins	  have	  been	  identified,	  namely	  Orai1,	  Orai2,	  and	  
Orai3,	  with	  their	  ability	  to	  elicit	  Calcium-­‐Release	  Activated	  Calcium	  Current	  (CRAC)	  
respectively	  (Varnai,	  Hunyady	  et	  al.).	  Despite	  the	  important	  regulation	  of	  store	  Ca2+	  
of	  STIM	  and	  Orai,	  their	  contribution	  to	  cellular	  function	  has	  only	  been	  described	  in	  
immunological	  cells.	  Functional	  characterizations	  of	  the	  role	  that	  STIM1	  and	  Orais	  
contribute	  in	  synaptic	  plasticity	  will	  further	  the	  understanding	  of	  the	  involvement	  of	  
store	  Ca2+	  in	  plasticity	  events.	  
	  
Results	  
In	  order	  to	  investigate	  the	  specific	  functions	  of	  STIM1,	  Exon	  6	  was	  targeted.	  
“Floxed”	  STIM1	  (F/F)	  mouse	  lines	  were	  generated	  by	  ES	  cell-­‐mediated	  gene	  
targeting	  and	  subsequently	  crossed	  to	  Nestin	  promoter-­‐driven	  Cre	  line	  or	  CamKII	  
promoter-­‐driven	  Cre	  lines	  (Figure	  1A).	  STIM1	  knock	  out	  mice	  (F/F	  Nestin-­‐Cre)	  did	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not	  display	  any	  gross	  anatomical	  or	  phenotypical	  abnormalities.	  Western	  blot	  
analysis	  of	  forebrain	  lysates	  derived	  from	  P25	  day	  old	  STIM1-­‐KO	  mice	  showed	  
efficient	  excision	  and	  depletion	  of	  STIM1	  (Figure	  1B).	  STIM1	  protein	  is	  detectable	  
starting	  at	  P4	  and	  maintains	  peak	  expression	  from	  P17	  to	  adulthood	  (Figure	  1C).	  
Next,	  we	  examined	  expression	  and	  localization	  of	  STIM1	  in	  the	  brain	  with	  
biochemical	  sub-­‐cellular	  fractionation	  experiments	  utilizing	  sucrose	  and	  differential	  
centrifugation	  followed	  by	  SDS-­‐PAGE	  and	  Western	  blot	  analysis	  (Figure	  1D).	  STIM1	  
was	  found	  in	  membrane	  fractions	  including	  endoplasmic	  reticulum,	  crude	  
synaptosomal	  membrane,	  synaptosomal	  membrane	  and	  synaptic	  vesicle-­‐enriched	  
fractions.	  This	  finding	  is	  consistent	  with	  previous	  reports	  of	  STIM1	  expression	  in	  
heterologous	  cell	  system	  (Onodera,	  Pouokam	  et	  al.).	  Furthermore,	  we	  examined	  the	  
expressions	  of	  proteins	  that	  mediate	  synaptic	  plasticity	  such	  as	  AMPA	  receptors,	  
NMDA	  receptors	  and	  Calcineurin	  in	  the	  STIM1-­‐KO	  forebrains	  (Figure	  1D).	  No	  
appreciable	  difference	  in	  expression	  and	  localization	  of	  GluR1,	  GluR2,	  NR1,	  NR2A	  
and	  Calcineurin	  was	  detected	  with	  our	  fractionation	  assay.	  	  
Dr.	  David	  Linden	  and	  Dr.	  Joo	  Min	  Park	  from	  the	  Neuroscience	  Department	  at	  
Johns	  Hopkins	  School	  of	  Medicine	  employed	  a	  series	  of	  electrophysiology	  recordings	  
focusing	  on	  the	  Schaffer	  collateral-­‐CA1	  synapses	  in	  hippocampal	  slices	  and	  surveyed	  
STIM1-­‐KO	  for	  alterations	  in	  synaptic	  plasticity.	  STIM1-­‐KOs	  mediated	  by	  Nestin-­‐Cre	  
showed	  a	  selective	  deficit	  in	  NMDA-­‐LTD	  induced	  by	  low	  frequency	  stimulations	  
(Figure	  2A).	  We	  were	  also	  able	  to	  recapitulate	  the	  NMDA-­‐LTD	  deficit	  in	  STIM-­‐1	  KOs	  
mediated	  by	  CamKII-­‐	  Cre,	  which	  suggests	  that	  loss	  of	  STIM1	  in	  excitatory	  neurons	  
only	  was	  enough	  to	  disrupt	  NMDA-­‐LTD	  (Data	  not	  shown).	  To	  further	  understand	  the	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NMDA-­‐LTD	  deficit	  seen	  in	  the	  electrophysiology	  experiment,	  we	  employ	  
biochemical	  studies	  in	  the	  hippocampal	  slices.	  With	  the	  same	  hippocampal	  slice	  
preparation	  procedure,	  we	  induced	  NMDA-­‐LTD	  by	  incubating	  slices	  with	  20µM	  of	  
NMDA	  for	  3	  minutes	  followed	  by	  30	  minutes	  of	  recovery	  time	  (Figure	  2B).	  In	  
hippocampal	  control	  slices,	  the	  treatment	  with	  NMDA	  induced	  a	  significant	  
reduction	  of	  p-­‐GluR1	  (S845)	  indicative	  of	  GluR1	  endocytosis	  and	  NMDA-­‐LTD	  
occurrence.	  However,	  pretreatment	  with	  APV,	  a	  selective	  NMDA	  inhibitor	  abolished	  
the	  dephosphorylation	  of	  p-­‐GluR1	  (S845).	  In	  hippocampal	  slices	  derived	  from	  
STIM1-­‐KO	  mice,	  NMDA	  treatment	  did	  not	  lead	  to	  the	  reduction	  of	  p-­‐GluR1	  (S845)	  
suggesting	  that	  GluR1	  was	  retained	  on	  the	  surface	  and	  NMDA-­‐LTD,	  consistent	  with	  
the	  finding	  in	  electrophysiology	  studies	  (Figure	  2B).	  Moreover,	  pretreatment	  with	  
APV	  did	  not	  have	  any	  effect	  on	  p-­‐GluR1.	  To	  examine	  surface	  expression	  of	  GluR1	  
directly,	  we	  used	  DIV-­‐21	  dissociated	  hippocampal	  neuron	  cultures	  in	  combination	  
with	  surface	  biotinylation	  technique.	  Control	  neurons	  showed	  a	  reduction	  of	  surface	  
GluR1	  levels	  upon	  treatment	  with	  100µM	  of	  NMDA	  for	  5	  minutes	  followed	  by	  40	  
minutes	  of	  recovery	  (Figure	  2C).	  The	  reduction	  of	  surface	  GluR1	  by	  treatment	  with	  
NMDA	  was	  blocked	  by	  pretreatment	  with	  APV.	  However,	  in	  STIM-­‐KO	  neurons	  
neither	  the	  treatment	  with	  NMDA	  nor	  with	  additional	  pretreatment	  with	  APV	  
altered	  the	  surface	  expression	  of	  GluR1	  (Figure	  2C).	  Thus,	  biochemical	  examination	  
of	  GluR1	  surface	  expression	  in	  hippocampal	  slices	  and	  neuron	  cultures	  in	  STIM1-­‐KO	  
showed	  a	  deficit	  in	  NMDA-­‐LTD.	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With	  the	  finding	  that	  STIM1-­‐KOs	  have	  a	  deficit	  in	  NMDA-­‐LTD,	  we	  surveyed	  
other	  forms	  of	  synaptic	  plasticity	  by	  electrophysiology	  studies.	  DHPG	  mediated	  
mGluR-­‐LTD	  studies	  showed	  comparable	  results	  in	  hippocampal	  slices	  from	  STIM1-­‐
KOs	  and	  controls	  (Figure	  3A).	  Moreover,	  mGluR-­‐LTD	  elicited	  by	  pair	  pulse-­‐low	  
frequency	  stimulations	  (PP-­‐LFS)	  in	  the	  presence	  of	  NMDA	  receptor	  inhibitor	  APV,	  
was	  also	  preserved	  in	  STIM1-­‐KOs	  (Figure	  3B).	  Paired-­‐pulse	  ratio	  studies	  and	  fiber	  
volley	  amplitude	  studies	  showed	  presynaptic	  release	  and	  synaptic	  transmission	  are	  
not	  altered	  in	  the	  STIM1-­‐KOs	  (Figures	  3C-­‐D).	  	  Two	  different	  forms	  of	  LTP	  were	  also	  
examined	  in	  hippocampal	  slices	  from	  STIM1-­‐KOs	  and	  littermate	  controls.	  LTP	  
induced	  by	  Theta	  Burst	  Stimulation	  (TBS)	  remained	  intact	  in	  STIM1-­‐KOs	  (Figure	  
4A).	  LTP	  induced	  by	  High	  Frequency	  Stimulation	  (HFS)	  was	  also	  preserved	  in	  
STIM1-­‐KOs	  in	  comparison	  to	  control	  littermates	  (Figure	  4B).	  While	  mGluR-­‐LTD	  and	  
different	  forms	  of	  LTP	  remained	  intact	  in	  STIM1-­‐KOs,	  we	  next	  examined	  a	  
phenomena	  described	  as	  mGluR	  priming	  of	  NMDA-­‐LTP.	  It	  has	  previously	  been	  
documented	  that	  ER	  Ca2+	  store	  release	  can	  be	  triggered	  by	  mGluR	  activation	  
followed	  by	  Diacylglycerol	  and	  IP3	  generation	  to	  activate	  IP3	  receptors	  (Abdul-­‐
Ghani,	  Valiante	  et	  al.).	  Furthermore,	  store	  Ca2+	  also	  participates	  in	  LTP	  since	  
depletion	  of	  Ca2+	  store	  with	  application	  of	  thapsigargin	  inhibits	  LTP	  (Cong,	  Takeuchi	  
et	  al.).	  	  We	  examined	  mGluR	  priming	  of	  NMDA-­‐LTP	  and	  argue	  that	  any	  alterations	  
would	  reveal	  that	  integrity	  and	  the	  requirement	  of	  functional	  Ca2+	  store	  refilling	  
mediated	  by	  STIM1	  is	  essential	  in	  synaptic	  plasticity.	  DHPG	  pretreatment	  followed	  
by	  HFS	  showed	  an	  increase	  in	  fEPSP	  In	  control	  hippocampal	  slices	  compared	  to	  
conditions	  where	  only	  HFS	  was	  applied	  (Figure	  5).	  This	  observation	  demonstrated	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that	  prior	  mGluR	  activation	  followed	  by	  elicitation	  of	  LTP	  produced	  a	  more	  robust	  
LTP.	  However,	  in	  the	  STIM1-­‐KO	  hippocampal	  slices,	  DHPG	  stimulation	  prior	  to	  HFS	  
did	  produce	  a	  normal	  LTP	  but	  not	  a	  more	  robust	  LTP	  upon	  comparison	  with	  HFS	  
only	  (Figure	  5).	  This	  deficit	  suggests	  that	  although	  mGluR-­‐LTD	  and	  HFS-­‐LTP	  
remained	  intact	  in	  STIM1-­‐KO,	  however,	  stringent	  requirement	  of	  STIM1	  remains	  
under	  specific	  and	  multi-­‐faceted	  plasticity	  paradigm.	  
In	  collaboration	  with	  Dr.	  Alena	  Savonenko	  in	  the	  Department	  of	  
Neuropathology	  at	  Johns	  Hopkins	  School	  of	  Medicine,	  we	  assess	  the	  impact	  of	  5-­‐
month-­‐old	  male	  STIM1-­‐KOs	  and	  littermate	  controls	  in	  behavioral	  studies.	  STIM1-­‐
KOs	  showed	  normal	  levels	  of	  anxiety	  and	  motor	  activity	  in	  novel	  environments	  
(Figure	  6A-­‐B).	  Furthermore,	  learning	  and	  memory	  test	  revealed	  that	  spatial	  working	  
memory	  was	  intact	  (Figure	  6C-­‐E).	  To	  test	  for	  NMDA	  receptor	  function,	  we	  employed	  
dizocilpine	  (MK-­‐801),	  a	  noncompetitive	  NMDA	  receptor	  antagonist.	  STIM1-­‐KOs	  
showed	  significantly	  lower	  motor	  activation	  induced	  by	  MK-­‐801	  in	  comparison	  to	  
littermate	  controls	  (Figure	  7).	  	  
	  
Discussion	  
Synaptic	  plasticity	  is	  the	  ability	  of	  synapse	  to	  be	  strengthened	  or	  weakened	  
by	  activity	  dependent	  process	  and	  underlies	  learning	  and	  memory.	  Diseases	  of	  
cognition	  impact	  the	  ability	  of	  individuals	  to	  acquire	  and	  store	  information	  that	  is	  
mediated	  by	  the	  synapse	  (Paoletti,	  Bellone	  et	  al.).	  In	  neurons	  ER	  contributes	  to	  the	  
regulation	  of	  calcium	  in	  a	  multi-­‐faceted	  fashion.	  ER	  serves	  as	  a	  calcium	  buffer	  by	  up-­‐
taking	  calcium	  influx	  from	  surface	  calcium	  transporters	  at	  the	  dendrites	  locally	  and	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at	  the	  cellular	  level	  globally.	  ER	  also	  contributes	  to	  the	  rise	  of	  calcium	  level	  in	  
specific	  “hot	  spots”	  in	  response	  to	  synaptic	  activation	  via	  mGluR-­‐triggered	  IP3	  
production.	  The	  stringent	  regulation	  of	  local	  calcium	  concentration	  is	  necessary	  to	  
mediate	  plasticity	  phenomena	  and	  ensure	  cellular	  integrity.	  Thus	  examinations	  of	  
molecular	  mechanisms	  of	  ER	  calcium	  regulations	  and	  contribution	  to	  mediate	  
synaptic	  activities	  afford	  a	  better	  understanding	  of	  synaptic	  plasticity.	  
We	  identified	  synaptic	  plasticity	  deficits	  in	  NMDA-­‐LTD	  and	  mGluR	  priming	  of	  
LTP	  in	  the	  Nestin-­‐	  and	  CamKII-­‐	  Cre	  mediated	  STIM1	  conditional	  knockouts	  in	  this	  
study.	  These	  deficits	  are	  rather	  specific	  since	  mGluR	  mediated	  LTD	  and	  various	  
forms	  of	  LTP	  are	  intact	  in	  the	  STIM1-­‐KOs.	  The	  finding	  that	  NMDA-­‐LTD	  is	  abolished	  
was	  further	  substantiated	  by	  biochemical	  studies	  that	  indicate	  GluR1	  
dephosphorylation	  was	  blunted.	  Previous	  studies	  have	  demonstrated	  that	  
Calcineurin	  is	  the	  key	  phosphatase	  regulating	  GluR1	  (S845)	  (Snyder,	  Galdi	  et	  al.).	  
Calcineurin	  activity	  is	  directly	  correlated	  with	  cytosolic	  Ca2+	  levels	  (Baumgartel	  and	  
Mansuy).	  Our	  study	  showed	  that	  the	  expression	  and	  localization	  of	  Calcineurin	  was	  
not	  altered	  in	  the	  STIM1-­‐KOs	  thus	  it	  suggests	  that	  the	  activation	  of	  Calcineurin	  in	  
STIM1-­‐KOs	  may	  be	  disrupted	  due	  to	  lower	  cytosolic	  Ca2+	  levels.	  Future	  studies	  
utilizing	  STIM1-­‐KOs	  crossed	  with	  conditionally	  expressed	  genetically	  encoded	  Ca2+	  
indicator	  GCaMP3	  would	  be	  valuable	  to	  examine	  store	  and	  cytosolic	  Ca2+	  levels	  by	  
imaging	  acute	  brain	  slices	  using	  2-­‐photon	  microscopy.	  Furthermore,	  expression	  of	  a	  
FRET-­‐based	  Calcineurin	  activity	  sensor	  that	  Dr.	  Jin	  Zhang	  in	  the	  Neuroscience	  
Department	  at	  Johns	  Hopkins	  University	  has	  developed,	  in	  STIM1-­‐KO	  dissociated	  
neuronal	  cultures	  would	  be	  valuable	  to	  assess	  Calcineurin’s	  activity.	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NMDA	  receptor	  hypo-­‐function	  have	  been	  associated	  with	  many	  psychiatric	  
diseases	  (Paoletti,	  Bellone	  et	  al.).	  Furthermore,	  calcineurin	  deregulation	  has	  also	  
been	  demonstrated	  to	  be	  involved	  in	  schizophrenia,	  Huntington’s	  Disease	  and	  
Alzheimer’s	  Disease	  (Monti,	  Berteotti	  et	  al.)	  (Reese	  and	  Taglialatela)	  (Ermak,	  Hench	  
et	  al.).	  Behavioral	  tests	  with	  STIM1-­‐KOs	  showed	  that	  spatial	  working	  memory	  
remained	  intact.	  Furthermore,	  anxiety	  levels	  in	  open	  field	  and	  plus	  maze	  assays	  
remained	  normal.	  The	  reduced	  response	  to	  psychostimulant	  MK-­‐801	  in	  the	  STIM1-­‐
KOs	  is	  a	  curious	  one	  and	  would	  be	  interesting	  to	  compare	  to	  amphetamine	  induced	  
motor	  activation.	  In	  comparison	  of	  MK-­‐801	  to	  amphetamine,	  differentiation	  of	  
glutamatergic	  and	  dopaminergic	  networks	  could	  be	  made	  and	  further	  
understanding	  of	  motor	  activation	  mechanisms	  could	  be	  gained.	  Conditional	  
calcineurin	  knockout	  mice	  showed	  a	  selective	  NMDA-­‐LTD	  deficit	  and	  delay	  in	  
extinction	  of	  fear	  memory.	  Since	  our	  data	  strongly	  support	  the	  notion	  that	  
Calcineurin	  activity	  are	  reduced	  in	  the	  STIM1-­‐KOs,	  it	  would	  be	  interesting	  to	  
examine	  facilitation	  of	  fear	  acquisition	  and	  fear	  extinction	  in	  STIM1-­‐KOs.	  Ongoing	  











































































































































	  	  	  	  	  	  	  	  	   	  
	  

































Conclusions	  and	  Future	  Directions	  
	  
Learning	  and	  memory	  relies	  on	  the	  ability	  of	  the	  synaptic	  connection	  
network	  to	  alter	  their	  efficacy	  in	  response	  to	  activity	  termed	  synaptic	  plasticity.	  
Proper	  cognitive	  function	  requires	  neurons	  to	  maintain	  homeostasis	  and	  elicit	  
different	  modes	  of	  synaptic	  plasticity	  in	  an	  activity-­‐dependent	  manner.	  mTOR	  is	  
ubiquitously	  expressed	  in	  the	  central	  nervous	  system	  and	  its	  signaling	  pathway	  
mediate	  cellular	  functions	  to	  maintain	  homeostasis.	  Aberrant	  activation	  or	  the	  
blunting	  of	  stimuli	  induced	  activity	  of	  the	  mTOR	  signaling	  pathway	  disrupts	  the	  
ability	  of	  the	  neurons	  to	  adapt	  and	  function.	  mTOR	  signaling	  pathway	  in	  neurons	  is	  
coupled	  to	  plasma	  membrane	  receptors	  that	  influence	  synaptic	  plasticity.	  
Dysregulation	  of	  the	  mTOR	  signaling	  pathway	  due	  to	  genetic	  mutations	  or	  cellular	  
insults	  lead	  to	  devastating	  diseases	  such	  as	  cancer,	  diabetes,	  AD,	  ASD	  among	  others.	  
The	  use	  of	  rapamycin	  to	  inhibit	  mTOR	  activity	  in	  experiments	  have	  proved	  valuable	  
and	  revealed	  many	  cellular	  functions	  that	  are	  mTOR	  dependent.	  However,	  
conditional	  Rheb1	  knockout	  and	  over-­‐expresser	  mice	  provide	  significant	  
advantages	  in	  studying	  mTOR	  signaling	  in	  specific	  tissues	  and	  disease	  states.	  
Moreover,	  conditional	  Rheb1	  over-­‐expresser	  mouse	  may	  be	  utilized	  to	  mimic	  
disease	  states	  by	  specific	  expression	  in	  targeted	  tissues	  for	  in	  vivo	  studies.	  
Importantly,	  conditional	  Rheb1	  over-­‐expresser	  mouse	  may	  serve	  as	  a	  novel	  mouse	  
model	  platform	  for	  therapeutic	  discovery	  and	  treatment	  developments	  for	  diseases	  
that	  are	  correlated	  with	  elevated	  mTORC1	  activity.	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   Genetic	  and	  biochemical	  studies	  have	  provided	  a	  detailed	  mTOR	  signaling	  
pathway	  cascade	  with	  the	  revelation	  of	  the	  regulatory	  functions	  of	  its	  components.	  
Extra-­‐cellular	  ligand	  binding	  to	  plasma	  surface	  receptors	  initiates	  the	  canonical	  
mTOR	  signaling	  pathway.	  Subsequently,	  PI3K	  activation	  leads	  to	  the	  
phosphorylation	  of	  PDK1,	  which	  in	  turn	  activates	  Akt.	  Akt	  inhibits	  Tsc	  relieving	  its	  
inhibition	  on	  Rheb1	  thus	  activating	  mTORC1.	  Through	  a	  broad	  panel	  of	  
pharmacological	  drug	  screen,	  we	  uncovered	  a	  calcium	  dependent	  non-­‐canonical	  
mTORC1	  signaling	  pathway	  that	  could	  modulate	  mTORC1	  activity	  independently	  
from	  the	  canonical	  signaling	  pathway.	  mTORC1	  signaling	  directly	  correlates	  with	  
stimulation	  or	  inhibition	  of	  TRP	  channels,	  L-­‐type	  VDCC	  and	  Orai	  channels	  
demonstrated	  by	  treatment	  with	  pharmacological	  reagents	  and	  molecular	  
expression	  approaches.	  Further	  experiments	  showed	  that	  the	  non-­‐canonical	  
pathway	  is	  dependent	  on	  Ca2+/Calmodulin	  and	  is	  activated	  in	  the	  hippocampus	  
during	  exploration	  activities	  by	  mice.	  Neurons	  derived	  from	  AD	  mouse	  models	  
displayed	  “type	  III	  diabetes”-­‐like	  insensitivity	  to	  insulin	  stimulation	  of	  the	  canonical	  
pathway	  while	  the	  basal	  activity	  of	  mTORC1	  was	  elevated.	  The	  stimulatory	  input	  of	  
mTORC1	  in	  AD	  neurons	  may	  be	  attributed	  to	  the	  postulated	  disruptions	  in	  calcium	  
homeostasis	  (LaFerla).	  Detail	  studies	  of	  the	  molecules	  mediating	  the	  non-­‐canonical	  
pathway	  will	  provide	  further	  understanding	  of	  the	  novel	  pathway.	  Studies	  aim	  to	  
restore	  the	  canonical	  pathway	  in	  AD	  neurons	  and	  mice	  with	  pharmacological	  
inhibition	  of	  the	  non-­‐canonical	  pathway	  may	  provide	  insights	  to	  future	  therapeutic	  
treatments	  in	  AD.	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   The	  utility	  of	  the	  conditional	  myc-­‐Rheb1	  (S16H)	  mouse	  model	  is	  exemplified	  
through	  our	  biochemical,	  behavioral	  and	  electrophysiological	  experiments.	  Anti-­‐
Myc	  immunoprecipitations	  of	  myc-­‐Rheb1	  (S16H)	  under	  non-­‐denaturing	  conditions	  
revealed	  an	  intriguing	  and	  selective	  set	  of	  synaptic	  proteins,	  vesicle	  associated	  
proteins	  and	  enrichment	  of	  ubiquitinylated	  proteins.	  The	  proteins	  associated	  with	  
myc-­‐Rheb1	  (S16H)	  suggest	  a	  model	  where	  Rheb1	  traffics	  proteins	  destined	  for	  
degradation	  through	  lysosomal	  or	  proteosomal	  processing	  and	  generate	  amino	  
acids	  to	  facilitate	  mTORC1	  activation.	  Consistent	  with	  the	  proposed	  model,	  
pharmacological	  inhibition	  of	  proteosome	  or	  disruption	  of	  lysosomal	  activities	  lead	  
to	  reduction	  in	  mTORC1	  signaling	  (Bar-­‐Peled,	  Schweitzer	  et	  al.).	  Previous	  studies	  
demonstrated	  mGluR1/5	  activation	  induces	  mTORC1	  signaling	  and	  mGluR-­‐
dependent	  LTD	  is	  dependent	  on	  down	  regulation	  of	  surface	  receptors	  such	  as	  GluR2	  
(Huber,	  Kayser	  et	  al.)	  (Anggono	  and	  Huganir).	  	  Interesting	  we	  found	  mGluR5	  
associates	  with	  myc-­‐Rheb1	  (S16H)	  in	  a	  membrane	  dependent	  manner.	  mGluR5	  and	  
Rheb1	  may	  associate	  to	  form	  a	  signalosome-­‐like	  entity	  and	  together	  with	  
internalized	  GluR2	  destined	  for	  degradation	  could	  lead	  to	  the	  activation	  of	  mTORC1.	  
Future	  biochemical	  and	  immunocytochemistry	  experiments	  examining	  the	  activity-­‐
dependent	  modulation	  of	  mGluR5	  and	  its	  association	  with	  Rheb1	  is	  warranted.	  
	   Genetic	  mutations	  in	  TSC1/2,	  PTEN,	  FMR	  and	  EIF4E	  are	  highly	  correlated	  
with	  ASD-­‐like	  behaviors	  and	  elevated	  mTOR	  activity	  (Emamian).	  Researchers	  have	  
suggested	  that	  elevated	  mTOR	  activity	  appears	  to	  be	  the	  central	  theme	  in	  studies	  of	  
ASD	  (Emamian).	  Moreover,	  PET	  and	  MRI	  imaging	  studies	  have	  shown	  deficits	  in	  the	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striatum	  of	  ASD	  patients	  (Duchesnay,	  Cachia	  et	  al.)	  (Gaetz,	  Bloy	  et	  al.).	  Consistent	  
with	  the	  hypothesis,	  brain	  specific	  myc-­‐Rheb1	  (S16H)	  mice	  display	  ASD-­‐like	  
behavioral	  phenotypes	  with	  reduced	  social	  motivation,	  disruption	  in	  sensory-­‐gating	  
and	  reduced	  amphetamine-­‐induced	  locomotor	  activity.	  Biochemical	  
characterization	  of	  the	  striatum	  revealed	  feedback	  inhibition	  to	  dopamine	  receptor	  
signaling,	  disruptions	  in	  PKA	  pathway,	  Darpp32	  phosphorylation,	  and	  aberrant	  
activities	  in	  phosphatases.	  Furthermore,	  electrophysiological	  experiments	  showed	  
corticostriatal	  plasticity	  disruptions	  and	  insensitivity	  to	  D1R	  stimulation.	  The	  
feedback	  inhibition	  of	  dopamine	  receptors	  offers	  another	  example	  consistent	  with	  
diabetes,	  that	  persistent	  elevation	  of	  mTORC1	  activity	  results	  in	  disruption	  in	  
integration	  of	  signals	  as	  a	  response	  to	  extra-­‐cellular	  stimulation.	  Acute	  rapamycin	  
treatment	  revealed	  that	  mTOR	  activity	  participates	  in	  the	  amphetamine	  induced	  
locomotor	  activity.	  However,	  it	  did	  not	  rescue	  biochemical	  or	  behavioral	  phenotypes	  
in	  the	  myc-­‐Rheb1	  (S16h)	  over-­‐expresser	  mice.	  Future	  experiments	  employing	  a	  
chronic	  treatment	  of	  rapamycin	  or	  other	  pharmacological	  reagents	  to	  reduce	  mTOR	  
activity	  in	  the	  over-­‐expresser	  mice	  would	  provide	  insightful	  therapeutic	  treatment	  
strategies	  in	  ASD.	  	  
	   Much	  remains	  to	  be	  understood	  of	  the	  interplay	  between	  canonical	  and	  non-­‐
canonical	  mTOR	  signaling	  pathway	  and	  how	  they	  contribute	  to	  neural	  plasticity	  and	  
function.	  Persistent	  elevated	  mTORC1	  activity	  is	  associated	  devastating	  cognitive	  
diseases.	  The	  conditional	  myc-­‐Rheb1	  (S16H)	  mice	  allow	  for	  expression	  with	  
temporal	  and	  cell	  specific	  control.	  Future	  studies	  utilizing	  different	  promoter	  driven	  
Cre-­‐recombines	  crossed	  with	  myc-­‐Rheb1	  (S16H)	  may	  help	  to	  reveal	  the	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